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Matrix metalloproteinase 3 (MMP3) is well known as a secretory endopeptidase that degrades extracellular
matrices. Recent reports indicated the presence of MMPs in the nucleus (A. J. Kwon et al., FASEB J. 18:690–692,
2004); however, its function has not been well investigated. Here, we report a novel function of human nuclear
MMP3 as a trans regulator of connective tissue growth factor (CCN2/CTGF). Initially, we cloned MMP3 cDNA as
a DNA-binding factor for the CCN2/CTGF gene. An interaction between MMP3 and transcription enhancer
dominant in chondrocytes (TRENDIC) in the CCN2/CTGF promoter was confirmed by a gel shift assay and
chromatin immunoprecipitation. The CCN2/CTGF promoter was activated by overexpressed MMP3, whereas a
TRENDIC mutant promoter lost the response. Also, the knocking down of MMP3 suppressed CCN2/CTGF expres-
sion. By cytochemical and histochemical analyses, MMP3 was detected in the nuclei of chondrocytic cells in culture
and also in the nuclei of normal and osteoarthritic chondrocytes in vivo. The nuclear translocation of externally
added recombinant MMP3 and six putative nuclear localization signals in MMP3 also were shown. Furthermore,
we determined that heterochromatin protein gamma coordinately regulates CCN2/CTGF by interacting with
MMP3. The involvement of this novel role of MMP3 in the development, tissue remodeling, and pathology of
arthritic diseases through CCN2/CTGF regulation thus is suggested.
Connective tissue growth factor (CTGF/CCN2) is a member
of the CCN family of matricellular proteins and also has been
designated Hcs24, FISP12, IGFBP8, IGFBP-rP2, IG-M2, and
ecogenin. The other CCN proteins include Cyr61/CCN1,
NOV/CCN3, WISP1/CCN4, WISP2/CCN5, and WISP3/CCN6
(5, 26, 38, 39) as well, and they are structurally and functionally
related glycoproteins involved in cell differentiation, prolifer-
ation, adhesion, migration, and the formation of the extracel-
lular matrix. These matricellular functions of CCNs are in-
volved in physiological processes such as wound healing,
angiogenesis, morphogenesis, and embryogenesis as well as in
pathological states including fibrotic disorders, cancer, and ar-
thritis.
Earlier we showed that CCN2 promotes endochondral ossi-
fication by acting on chondrocytes, osteoblasts, and endothelial
cells (35, 37, 46). For example, CCN2 promotes physiological
chondrocytic proliferation and extracellular matrix (ECM) for-
mation. We also reported the regeneration of defects in artic-
ular cartilage in rat knee joints following treatment with re-
combinant CCN2 (36). Furthermore, ctgf-null mice were dead
on delivery and were characterized by defective angiogenesis,
the derangement of endochondral ossification, and dysmor-
phisms that occurred as a result of impaired chondrocyte pro-
liferation and an abnormal ECM composition within the hy-
pertrophic zone (24).
Matrix metalloproteinases (MMPs) are zinc-dependent en-
dopeptidases that are involved in the remodeling and turnover
of the ECM in physiological processes such as angiogenesis,
wound healing, embryogenesis, and morphogenesis as well as
in pathological states including cancers, myocardial infarction,
fibrotic disorders, rheumatism, and osteoarthritis (33, 49). Car-
tilage is a connective tissue that is constructed by chondrocytes
embedded within an ECM predominantly composed of colla-
gens and proteoglycans. ECM remodeling is achieved by reg-
ulating the production and degradation of specific ECM com-
ponents. MMPs, which comprise a large family of enzymes
with differential abilities to degrade specific ECM components,
play a vital role in this process. MMPs also cleave growth
factors and their binding proteins, thereby activating or inhib-
iting specific signaling events (15). Of note, the expression and
role of MMP3 have been investigated in the pathological status
of articular cartilage, such as in osteoarthritis and rheumatism
(1, 52).
Recent study has demonstrated the existence and functions
of intracellular MMPs and tissue inhibitors of metalloprotein-
ases (TIMPs). TIMP-1 accumulates in the cellular nuclei in
association with the cell cycle (54). Alternative splicing and
promoter usage generate an intracellular MMP11 isoform di-
rectly translated as an active MMP (31). MMP2 is found in the
nuclei of cardiac myocytes and is capable of cleaving poly-
(ADP-ribose) polymerase (PARP) in vitro (28). MMP3 also is
detected in the nuclei of hepatocytes and is involved in apop-
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tosis (47). MT1-MMP exhibits an intracellular cleavage func-
tion and causes chromosome instability, and it cleaves centro-
somal pericentrin in human cells but not in murine cells (12).
The mechanisms of CCN2/CTGF induction/production have
been well investigated (4, 26, 29); however, there have been
few approaches to identify directly binding regulatory proteins
of the CCN2/CTGF gene. Recently, we investigated cell type-
specific mechanisms of CCN2/CTGF gene regulation and
found a cis-acting element, transcription enhancer dominant in
chondrocytes (TRENDIC), between positions 202 and 180
from the transcription start site of CCN2/CTGF (7), a region
that previously had been predicted to contain an NF-1-like site
(7, 13). In our previous study, the strong production of CCN2
from chondrocytic cells was estimated to be mediated by
TRENDIC rather than by a juxtaposing Smad-binding element
(SBE) (7, 23). In this present study, we subsequently cloned
the cDNAs encoding TRENDIC-binding factors and unex-
pectedly found MMP3/stromelysin-1 to be one of them. We
then investigated whether or not MMP3 is localized in the
nuclei of chondrocytes in vitro and in vivo. Having found such
localization, we also examined if the nuclear MMP3 could bind
with enhancer sequences in the CCN2/CTGF promoter and
activate CCN2/CTGF transcription, and we showed that it did
so. Finally, we evaluated the properties of MMP3 as a tran-
scription factor by analyzing nuclear MMP3-associated pro-
teins (NuMAPs).
MATERIALS AND METHODS
HCS-2/8 cDNA phage library. The cDNA phage library was constructed by
using a ZAP cDNA synthesis kit (Toyobo, Osaka, Japan) and a ZAP express
predigested Gigapack cloning kit (Stratagene, La Jolla, CA) according to the
manufacturer’s protocols. Total RNA was prepared from HCS-2/8 cells by an
acid guanidinium-phenol-chloroform (AGPC) method. Polyadenylated RNA
was prepared from the total RNA by using an Oligotex-dT30 Super mRNA
purification kit (Takara, Otsu, Japan). First-strand cDNA was synthesized by
using linker primer 5-CTCGAGTTTTTTTTTTTT and 5-methyl-dCTP. Sec-
ond-strand cDNA was synthesized by using RNase H and DNA polymerase I.
The double-strand cDNA was blunted by using Pfu DNA polymerase. The cDNA
was added to a phosphorylated EcoRI adapter, digested by XhoI, and inserted in
a ZAP express vector digested with EcoRI and XhoI. The average length of the
insert cDNA of the library was confirmed by PCR to be approximately 2 kb.
Southwestern screening. We performed Southwestern screening as previously
described, with a slight modification (53). The Escherichia coli XL1-Blue MRF
strain was infected with the lambda phage library and then spread on NZY agar
plates containing 0.5 M isopropyl--D-thiogalactopyranoside (IPTG). Formed
plaques were lifted onto nitrocellulose membranes (GE Healthcare, Uppsala,
Sweden). The double-stranded DNA (dsDNA) of four tandem repeats of
TRENDIC was prepared by annealing the following oligonucleotides: 4
TRENDIC-s, 5-ACG CGT [(CTG TGA GCT GGA GTG TGC CAGC) CAG]4
CTC GAG-3; 4 TRENDIC-as, 5-CTC GAG [CTG (GCT GGC ACA CTC
CAG CTC ACAG)]4 ACG CGT-3. The annealed probe was end labeled with
[-32P]ATP and was applied to the membranes in binding buffer (10 mM
HEPES, pH 7.9, containing 50 mM KCl, 10 mM MgCl2, 0.1 mM EDTA, 1 mM
dithiothreitol [DTT], 0.25% skim milk, and 50 g/ml of denatured and undena-
tured salmon sperm DNA). After the membranes had been washed three times
with a wash buffer (10 mM HEPES, pH 7.9, containing 250 mM KCl, 10 mM
MgCl2, 0.1 mM EDTA, 1 mM DTT, and 0.25% skim milk), they were exposed
to X-ray films. The positive plaques were picked up for subsequent secondary
and tertiary screenings as well. The final cDNA clones in a pBK-cytomegalovirus
vector were obtained by in vivo excision using the E. coli XLOLR strain.
DNA sequencing and computer analysis. The cDNA cloned into each plasmid
was sequenced by the dideoxy chain termination method (42) with a BigDye
Terminator cycle sequencing ready reaction kit, version 2.0 (Applied Biosystems,
Foster City, CA), and an ABI PRISM 310 genetic analyzer (Applied Biosys-
tems). The sequences were analyzed by using BLASTn, Evidence Viewer, and
UniGene online services at the NCBI website (http://www.ncbi.nlm.nih.gov/).
These data on the cloned genes are summarized in Table 1.
Cell culture. The following human-derived cells were used: human chondro-
sarcoma-derived chondrocytic HCS-2/8 cells (40, 51), MDA-MB-231 breast car-
cinoma cells, HeLa cells derived from human cervical cancer, and SaOS-2 os-
teosarcoma-derived cells. A COS7 monkey kidney-derived cell line also was
used. Cells were cultured in Dulbecco’s modified Eagle’s minimum essential
medium (DMEM) supplemented with 10% fetal bovine serum (FBS) in humid-
ified air containing 5% CO2 at 37°C. For immunocytochemistry and internaliza-
tion studies, glass chamber slides (4 or 8 well) were coated with 50 g/ml of
collagen (Cellmatrix type I-C; Nitta-Gellatin, Osaka, Japan) for 30 min before
cells were seeded.
Antibodies. We used the following anti-MMP3 antibodies: anti-MMP3 N-
terminal region (5052; Sigma, St. Louis, MO), anti-MMP3 hinge region (4802;
Sigma), anti-MMP3 C-terminal domain (4927; Sigma), and anti-MMP3 catalytic
(CAT) domain antibody (4190; Sigma). We also used anti-CCN2/CTGF (AF660;
R&D), anti-histone H3 (06-599; Upstate), anti-Sox6 (S7193; Sigma), anti--
tubulin immunoglobulin G1 (IgG1) (T9026; Sigma), anti-cathepsin D (C-20;
Santa Cruz Biotech, Santa Cruz, CA), anti-lamin A/C monoclonal IgM (sc-7293;
Santa Cruz), and anti--actin (AC-74; Sigma). We used the following antibodies
to detect tags: anti-Flag M2 (Sigma), anti-Myc tag (Abcam, Cambridge, United
Kingdom), and anti-glutathione S-transferase (anti-GST) (GE Healthcare) an-
tibodies. An antidigoxigenin alkaline phosphatase-conjugated Fab (Roche,
Basel, Switzerland) was used in electrophoresis mobility shift assays (EMSA).
For Western blotting, we used horseradish peroxidase-conjugated secondary
antibodies against anti-mouse IgG (Amersham) and anti-rabbit IgG (Dako,
Copenhagen, Denmark). An anti-rabbit IgG rhodamine conjugate (Sigma) was
used for immunostaining. We used these antibodies at the concentrations in-
structed by the manufacturer. The MMP3 enzyme-linked immunosorbent assay
(ELISA) kit was purchased from Daiichi Pure Chemicals (Tokyo, Japan).
Preparation of subcellular fraction proteins. The nuclear and cytoplasmic
proteins were prepared by using a CelLytic NuCLEAR extraction kit (Sigma)
according to the manufacturer’s protocol. The subcellular fractions were pre-
pared by using a ProteoExtract subcellular proteome extraction kit (Calbiochem,
San Diego, CA) according to the manufacturer’s protocol. Total cell lysate was
prepared by using a CelLytic M reagent (Sigma) according to the manufacturer’s
protocols. The protease inhibitor cocktail (Sigma) was added at the appropriate
steps.
SDS-PAGE and Western blot analysis. Extracted proteins were heated at 95°C
for 5 min in sodium dodecyl sulfate (SDS) sample buffer in the presence of 5%
2-mercaptoethanol and separated by SDS-polyacrylamide gel electrophoresis
(PAGE) in 12% polyacrylamide gel. Alternatively, proteins were heated at 70°C
for 10 min in lithium dodecyl sulfate sample buffer containing 50 mM DTT and
TABLE 1. cDNA clones of TRENDIC binding factor candidatesa
Length of cloned cDNA Gene name Expression profile in UniGene Chromosomalposition
GenBank
accession no.
The last 1,857 bp of a
total of 3,733 bp
FLJ14525 Ubiquitous 1q42.13-q43 NM_032800
1,821 bp (FL) MMP3 Connective tissue, cartilage, bone,
osteoarthritis cartilage, and
nonneoplasia
11q22.3 NM_002422
2,036 bp (FL) DDOST Ubiquitous 1p36.1 NM_005216
a The DNA sequences were 100% matched to the known genes in the NCBI GenBank database. Their GenBank accession numbers, expression tendency as
determined by the UniGene expressed sequence tag database, and their chromosomal positions are shown. FL, full-length cDNA.
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were separated in a 10% Bis-Tris NuPAGE gel (Invitrogen) in morpholinepro-
panesulfonic acid running buffer containing an antioxidant. Semidry electro-
blotting was carried out using a polyvinylidene difluoride membrane (Hybond P;
GE Healthcare). The membrane was blocked in Tris-buffered saline containing
0.05% Tween 20 (TBST) and 5% skim milk for 30 min at room temperature
(RT). After being blocked, the membrane was incubated with the primary anti-
body overnight at 4°C and subsequently was incubated with the secondary anti-
body for 1 h at RT in the blocking solution. The blot was visualized by using an
enhanced chemiluminescence (ECL) Western blotting analysis system (GE
Healthcare) with chemiluminescence detection. The photogram was obtained by
autoradiography or by using an ECL minicamera (GE Healthcare). The band
signals obtained by Western blotting were quantified by using ImageJ, version
1.37 (Wayne Rasband, NIH).
Recombinant proteins, MMP3 activator, and inhibitors. A recombinant hu-
man proenzyme MMP3 (rhMMP3; R&D) was purchased and used for the
molecular weight control and the internalization assay. For other experiments,
we used our purified rhMMP3, prepared as described below. Organomercurial
(4-aminophenyl)mercuric acetate (APMA) (Sigma) was dissolved in 50 mM
NaOH. Active MMP3 was prepared by incubating proenzyme MMP3 (final
concentration, 83.3 nM) with 1 mM of APMA in Tris buffer (50 mM Tris-HCl,
pH 7.5, containing 5 mM CaCl2 and 0.05% Triton X-100) at 37°C for 4 h. All
MMP inhibitors were purchased from Calbiochem and were dissolved and stored
in dimethyl sulfoxide (DMSO). Before use, they were diluted 100-fold once in a
cell culture medium (1% DMSO) and then added to cultured cells (final con-
centration, 0.01% DMSO). Transforming growth factor  (TGF-) (10 ng/ml)
was purchased from Peprotech (Rocky Hill, NJ).
Stromelysin endopeptidase activity assay. The stromelysin endopeptidase ac-
tivity assay was carried out by using the fluorescence resonance energy transfer
peptide substrate Mca-RPKPVE-Nval-WRK(Dnp)-NH2 fluorogenic substrate II
(R&D, Minneapolis, MN) (32). The substrate (10 M) was mixed with enzyme
or nuclear extract in a Tris buffer (50 mM Tris-HCl, pH 7.5, containing 5 mM
CaCl2 and 0.05% Triton X-100) and incubated at 37°C. The relative fluorescence
units (RFUs) of the reactant in a 96-well black plate were measured by using a
Fluoroskan AscentFL (Labsystem, Helsinki, Finland).
Immunocytochemistry. For immunocytochemistry, cells were fixed in 4% (wt/
vol) paraformaldehyde in phosphate-buffered saline (PBS) for 15 min, washed in
TBS, and permeabilized with 0.2% Triton X-100 for 15 min. Incubation with
primary and secondary antibodies was performed in PBS containing 1.5% nor-
mal goat serum and 0.05% Triton X-100 at RT for 1 h, respectively. After three
washes with TBS, the mounting and DNA staining were performed by using
ProLong gold antifade reagents with 4,6-diamino-2-phenylindole (DAPI) (Mo-
lecular Probes, Invitrogen). Cells were observed with an immunofluorescence
microscope (Biozero; Keyence, Osaka, Japan) or a Radiance 2100 laser scanning
system (Bio-Rad).
Conjugation of Cy3 to rhMMP3. For the conjugation of Cy3 to rhMMP3, the
Tris-based solvent of rhMMP3 was replaced with sodium carbonate-sodium
bicarbonate buffer (pH 9.3) by use of a Microcon YM-30 (Millipore, Billerica,
MA), and the concentration was adjusted to 100 g/ml. MMP3 (50 l) was added
to a vial of Cy3 monoreactive dye (GE Healthcare) and was incubated at RT for
30 min with mixing every 10 min. The labeled MMP3 was desalted and separated
from the unconjugated Cy3 on a MicroSpin G-25 column (GE Healthcare)
preequilibrated with PBS.
Internalization studies. The cells in chamber slides were washed once with
prewarmed serum-free medium and incubated with Cy3-MMP3 (1 g/ml) in the
serum-free medium at 37°C for 5, 10, 15, 30, or 60 min and subsequently were
fixed with 4% paraformaldehyde in PBS for 15 min. The cells were stained with
10 nM Sytox green nucleic acid stain (Molecular Probes, Invitrogen) in TBS for
20 min and mounted in ProLong antifade reagents (Molecular Probes, Invitro-
gen). The cells were observed by confocal laser microscopy as described below,
and Cy3-positive cells were classified into three groups: cells with cytoplasm-
dominant signals, cells with both cytoplasmic and nuclear signals, and cells with
nucleus-dominant signals.
Confocal laser scanning microscopy. Confocal laser scanning was carried out
with a Radiance 2100 laser scanning system equipped with an argon and krypton
laser (excitation wavelengths of 488 and 568 nm) (Bio-Rad) through an Eclipse
TE2000-U microscope (Nikon) with a 60 objective lens. The scan was visual-
ized with the software Laser Sharp 2000 (Bio-Rad).
NLS analysis. Nuclear localization signals (NLSs) in MMP3 were predicted by
the PSORTII program (http://psort.nibb.ac.jp/helpwww2.html#src) (34). Several
arginine- and lysine-rich sequences in MMP3 also were selected for analysis.
pEGFP-NLSs were constructed as described below. COS7 cells were cultured in
the 4-well chamber slides and were transfected with 200 ng of a series of pEGFP-
NLS constructs by the aid of Fugene 6 transfection reagent (Roche). After being
cultured for 24 h, cells were fixed with 4% formaldehyde in PBS and mounted
with a fluorescent mounting medium (Dako). The subcellular localization of the
enhanced green fluorescent protein (EGFP) was visualized with confocal laser
scanning microscopy.
EMSA. EMSA was carried out as described previously (7) by using a digoxi-
genin system (Roche). For preparing the probes, sense and antisense oligonu-
cleotides were annealed in a TEN buffer (10 mM Tris, 1 mM EDTA, 100 mM
NaCl, pH 8.0) and labeled with digoxigenin-11-UTP by using terminal transferase
(Roche). The following pairs of oligonucleotides were annealed: TRENDIC-s
(5-CTG TGA GCT GGA GTG TGC CAG C-3) and TRENDIC-as (5-GCT
GGC ACA CTC CAG CTC ACA G-3); BCE1/TbRE-s (5-CTG AGT GTC
AAG GGG TCA GGA-3) and BCE1/TbRE-as (5-TCC TGA CCC CTT GAC
ACT CAG-3); and Seq2-s (5-GAA TCA GGA GTG GTG CGA AG-3) and
Seq2-as (5-CTT CGC ACC ACT CCT GAT TC-3). The cellular or nuclear
extract (5 g) was preincubated with antibodies for 15 min at RT. Subsequently,
60 fmol of probes was added to the 0.5 binding buffer [10 mM HEPES, pH 7.6,
containing 0.5 mM EDTA, 5 mM (NH4)2SO4, 0.5 mM DTT, 1% Tween 20, and
15 mM KCl] with 5 ng/ml of poly(dI-dC) for 15 min at RT. rhMMP3 (300 ng) was
incubated with 45 fmol of probe, 50 ng/ml of poly-L-lysine, and 5 ng/ml of
poly(dI-dC) in the binding buffers for 15 min. Electrophoresis was performed in
a 6% polyacrylamide Tris-borate-EDTA (TBE) gel in a 0.5 TBE buffer for 60
to 100 min. Electroblotting was carried out on a positively charged nylon mem-
brane (GE Healthcare). The UV cross-linking and detection of digoxigenin were
carried out according to the manufacturer’s protocols (Roche).
Probe CCN2p160, which contains a CCN2 promoter DNA fragment between
positions 292 and 137, was prepared from a plasmid template by PCR and
labeled with digoxigenin. For EMSA performed with rhMMP3, MMP3 inhibitor
(0.5 mM) was added to each reaction. For supershift assays, rhMMP3 and an
antibody (2 g) were preincubated at 4°C for 40 min before the addition of the
probes. For competitive EMSA, the recombinant protein and competitor were
preincubated at 4°C for 5 min before the addition of the probe. Poly-L-lysine (0.5
or 1.0 g/reaction) was used.
ChIP assay. The chromatin immunoprecipitation (ChIP) assay was carried out
according to the manufacturer’s protocol (Upstate) with a slight modification. A
half million HCS-2/8 cells were seeded in each well of a 6-well plate and were
cultured for 48 h with a medium change at 24 h. Formaldehyde (final concen-
tration, 1%) was added to the medium, and the cells were incubated for 10 min
at 37°C. The cells were washed twice and scraped in ice-cold PBS containing a
protease inhibitor cocktail (Sigma) and then centrifuged for 4 min at 200  g at
4°C. Subsequently, the cells were lysed in 200 l of SDS lysis buffer (50 mM
Tris-HCl, pH 8.1, containing 10 mM EDTA and 1% SDS) for 10 min on ice.
DNA was sheared by three 10-s rounds of sonication on ice by using a Handy
Sonic model UR-20P (Tomy Seiko, Tokyo, Japan) at 30% of maximum power.
After centrifugation at 10,000  g at 4°C for 10 min, the supernatant was diluted
10-fold in ChIP dilution buffer (16.7 mM Tris-HCl, pH 8, containing 167 mM
NaCl, 1.2 mM EDTA, 0.01% SDS, 1.1% Triton X-100, and protease inhibitor
cocktail), and 1% of it was retained as the input. The sample was precleared by
rotating it with 80 l (4%) of a 50% salmon sperm DNA–50% protein A-agarose
slurry (Upstate) for 30 min at 4°C. After a brief centrifugation, the supernatant
was rotated with or without the anti-MMP3 CAT domain antibody (1:500;
Sigma) overnight at 4°C and was further incubated after adding 60 l (3%) of the
50% salmon sperm DNA–50% protein A-agarose slurry at 4°C for 1 h. The
protein A-agarose–antibody–antigen complex was centrifuged at 300  g at 4°C
for 1 min, and the pellet was washed once with low-salt wash buffer (20 mM
Tris-HCl, pH 8.1, containing 150 mM NaCl, 2 mM EDTA, 0.1% SDS, and 1%
Triton X-100), once with high-salt wash buffer (20 mM Tris-HCl, pH 8.1, con-
taining 500 mM NaCl, 2 mM EDTA, 0.1% SDS, and 1% Triton X-100), once
with LiCl wash buffer (10 mM Tris-HCl, pH 8.1, containing 0.25 M LiCl, 1%
NP-40, 1% deoxycholate, and 1 mM EDTA), and twice with TE buffer (10 mM
Tris-HCl, pH 8.0, 1 mM EDTA). The antigen complex was eluted by being mixed
and rotated in 250 l of freshly prepared elution buffer (1% SDS, 0.1 M
NaHCO3). The elution step was repeated, and the eluates were combined. A 4%
volume of 5 M NaCl was added to the eluate and to the input sample. The
cross-linked chromatin complex was reversed by being heated at 65°C for 4 h, and
DNA was purified using QIAquick spin columns (Qiagen, Hilden, Germany).
PCR was carried out using Prime STAR HS DNA polymerase (Takara) accord-
ing to the manufacturer’s protocol. Ten percent of the total purified DNA was
used for the PCR in 50 l of reaction mixture. The 204 bp of CCN2 enhancer
fragment between 292 and 88 was amplified by using the primer pair Seq2-s
(5-GAA TCA GGA GTG GTG CGA AG-3) and 110bp-as (5-ATT CCT CGC
ATT CCT CCC CAC CT-3) in 30 cycles of PCR under the following conditions:
98°C for 10 s, 62°C for 30 s, and 72°C for 30 s. The 215-bp cDNA of GAPDH was
amplified by using the primer pair GAPDH NEO LCL (5-GCC AAA AGG
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GTC ATC ATC TC-3) and GAPDH NEO LCR (5-GTC TTC TGG GTG
GCA GTG AT-3) in 30 cycles of PCR under the following conditions: 98°C for
10 s, 65°C for 20 s, and 72°C for 20 s. The PCR products were analyzed by 2%
agarose gel electrophoresis.
Plasmid constructs. The cDNA of MMP3 cloned in pBK-CMV by Southwest-
ern screening was subcloned into the p3xFlag-myc vector (Sigma) via a PCR-
based method, and it was designated p3Flag-MMP3-myc. A series of CTGF/
CCN2 promoter-luciferase reporter constructs were described previously (7–9).
The cDNA of MMP3 was subcloned from the p3Flag-MMP3-myc vector to the
pCold-TFII vector for expression in E. coli. Expression plasmids for MMP3
domains (full length [FL] and active forms, the prodomain, the combination of
the CAT and Hinge domains [CATHinge], and hemopexin-like repeat [PEX])
and MMP3 point mutants (H218R, H228R, and H218/228R) were constructed
via a PCR-mediated mutagenesis method. The cDNA of GST was recombined
from the pGEX-6P-3 vector (Amersham) to the pCold-TFII vector (Takara)
using HindIII and SalI sites by a PCR-mediated method to constitute pCold-
GST. The cDNAs of heterochromatin protein 1 (HP1), HP1, NF45, nuclear
receptor corepressor 1 (NCoR1), and chromatin assembly factor p48/retinoblas-
toma binding protein 4/7 (CAFp48/RBBP4) were prepared from mRNA of
HCS-2/8 cells via reverse transcription-PCR and were subcloned into the pCold-
GST vector. For the preparation of pEGFP-NLS constructs, sense and antisense
oligonucleotides for NLSs were annealed and subcloned into the pEGFP-C1
vector (Clontech, Takara) between XhoI and EcoRI sites. These constructs are
designated pEGFP-NLS0 to pEGFP-NLS5. All constructs were confirmed by
DNA sequencing.
pcDNA3.1()-3HA (p3xHA) was constructed by inserting a three-hemagglutinin
(HA) tag in the pcDNA3.1() vector (Invitrogen). pcDNA3.1()HP1-3HA,
pcDNA3.1()NF45-3HA, pcDNA3.1()RBBP4-3HA, and pcDNA3.1()DDOST-
3HA were constructed via PCR-mediated subcloning. All constructs were con-
firmed by DNA sequencing and Western blotting.
DNA transfection and luciferase assay. Cationic liposome-mediated DNA
transfection was carried out with a Fugene 6 transfection reagent according to
the manufacturer’s optimized methodology (Roche). For reporter gene assays,
cells were seeded in 12-well plates and cultured for 12 to 24 h. Subsequently, cells
were transfected with a total of 1 g of plasmid DNA in the reporter/effecter/
control ratio of 2:1:1 or 10:10:1. Medium was changed 20 h after the transfection.
After being cultured for a further 24 h, cells were lysed in 200 l of 1 passive
lysis buffer (Promega, Madison, WI) with gentle rocking for 20 min and were
collected. Luciferase assays were carried out by using a Dual Glo luciferase assay
system (Promega), as described previously, on a smaller scale (17). Relative
luciferase activities were calculated as the ratios of firefly luciferase activity to
Renilla luciferase activity.
siRNA and gene knockdown studies. The specific short interfering RNAs
(siRNAs) were predicted and synthesized by iGENE (Sapporo, Japan). The
siRNA targeting MMP3 (siM3-1369) was an oligoduplex of 5-GAG UUU GAC
CCA AAU GCA AAG AAA G-AG-3 (sense) and 5-CUU UCU UUG CAU
UUG GGU CAA ACU C-AU-3 (antisense). The control was an oligoduplex of
5-UUA GUG GUG AAU AUA ACA AGC UCU C-AG-3 (sense) and
5-GAG AGC UUG UUA UAU UCA CCA CUA A-AU-3 (antisense). This
control double-strand RNA (dsRNA) was predicted not to be homologous to
known mRNA sequences of vertebrates. For transient gene knockdown studies,
cells were seeded in 12-well plates and cultured for 24 h. Cells were transfected
with siRNA (25 nM) with the aid of 1 l of Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) and were further cultured for 24 h. After being trypsinized, the
cells were collected by centrifugation at 300 g for 5 min. Cytoplasmic RNA was
isolated by using RNeasy minicolumns (Qiagen) according to the manufacturer’s
protocol.
For reporter gene assays, 500 ng of the reporter construct and 50 ng of the
phRL-TK(int) control vectors (Promega) were transfected at 8 h after the
siRNA transfection. The medium was changed 24 h later, and the cells were lysed
at 48 h after the reporter transfection. The luciferase assay was performed as
described above.
A retroviral vector (pSINsi-hU6; Takara, Otsu, Japan) that expresses the short
hairpin RNA (shRNA) targeting MMP3 (shMMP3) or scrambled shRNA was
constructed by inserting the following sense-loop-antisense DNA sequence:
shMMP3, 5-G AGT TTG ACC CAA ATG CAA AGA AAG GTG TGC TGT
CCC TTT CTT TGC ATT TGG GTC AAA CTC-3, or scrambled shRNA, 5-T
TAG GGG ATA AGT ACG GTT GAA TCT GTG TGC TGT CCA GAT TCA
ACC GTA CTT ATC CCC TAA-3. 293T cells were cotransfected with an
established combination of viral protein expression vectors, and then the condi-
tioned media were prepared. HCS-2/8 cells (2  105/well of 6-well plates) were
cultured overnight, and then the medium was changed to 1 ml of DMEM
containing 10% FBS, 8 g Polybrene, and 40 l of the virus-containing condi-
tioned medium. One milliliter of DMEM containing 10% FBS was added 6 h
after the infection. The medium was changed every 3 days. Total RNA was
prepared 2 weeks after the infection by using Isogen (Nippongene, Tokyo,
Japan). cDNA synthesis and real-time PCR were performed as described below.
Reverse transcription and real-time PCR. Reverse transcription was carried
out with 500 ng of the cytoplasmic RNA by using Omniscript reverse transcrip-
tase (Qiagen) and oligo(dT) according to the manufacturer’s protocol. The
real-time PCR was carried out as described previously (7) using a LightCycler
system (Roche) with Sybr green (Toyobo) according to the manufacturer’s di-
rections. The PCR conditions were as follows: primary denaturation at 95°C for
30 s, followed by 45 cycles of PCR at 95°C for 5 s, 65°C (for MMP3 and CCN2)
or at 60°C (for GAPDH) for 10 s, and 72°C for 15 s. The signals were collected
at 72°C in every cycle. The specific primers for real-time PCR were designed and
synthesized by NGRL (Sendai, Japan) as MMP3LCL (5-CAG GCT TTC CCA
AGC AAA TA-3) and MMP3LCR (5-GTG CCC ATA TTG TGC CTT CT-3)
for human MMP3. The nucleotide sequences of the primer pairs for CCN2 and
GAPDH were previously described (7).
Coimmunoprecipitation and LC-MS. The anti-MMP3 antibody affinity col-
umns were prepared by using antibodies described above and a ProFound mam-
malian coimmunoprecipitation kit (Pierce, Rockford, IL) according to the man-
ufacturer’s protocol. Eluate (20% of the total) was used for the subsequent
tryptic digestion using an in-solution tryptic digestion and guanidination kit
(Pierce). The eluted proteins were reduced in ultrapure water containing 5 mM
DTT and 25 mM ammonium bicarbonate at 95°C for 5 min. To minimize
disulfate bond formation and side chain modification, the alkylation of the
samples was carried out by adding iodoacetamide (IAA; 10 mM at final concen-
tration) at RT for 20 min in the dark. The protein samples were digested by
adding activated trypsin (final concentration, 3 ng/l) and incubating them at
30°C overnight. Formic acid was added (final concentration, 0.1%). One micro-
liter of the peptide samples was applied to nanospray high-performance liquid
chromatography chip-ion trap-mass spectrometry/mass spectrometry (MS/MS)
with an Agilent 1100 liquid chromatography (LC)/MSD Trap XCT Ultra series
system (Agilent Technologies, Santa Clara, CA). The MS and MS/MS data were
analyzed by the data analysis software Spectrum Mill, version 3.3 (Agilent). The
cutoff score for proteins was 8.0. The score was defined based on the covering
rate for amino acid sequences and the frequency of detected fragments. To
remove the background signals, we excluded the data obtained with a control
IgG column from those obtained with the anti-MMP3 columns.
Recombinant protein preparation. Recombinant proMMP3, GST, GST-fused
HP1, HP1, NF45, NCoR1(1-152), and CAFp48/RBBP4 were prepared by a
cold shock system (Takara) according to the manufacturer’s protocol. These
recombinant proteins were designed to be fused with a trigger factor (Takara),
which improves protein solubility. E. coli Rosetta2(DE3)pLysS-competent cells
(Invitrogen) were transformed by the pCold-derived vectors described above.
Transformed clones were cultured in 2 ml of Luria-Bertani broth containing 500
g/ml of carbenicillin at 37°C for 8 h. Cells were further cultured in 10 to 500 ml
of the broth at 37°C until an optical density at 600 nm of between 0.4 and 0.5 was
reached. The induction of the protein synthesis was carried out by cooling the E.
coli at 15°C for 30 min and further shaking the sample for 24 h at 15°C after the
addition of 0.5 mM IPTG. Cellular pellets were obtained by centrifugation,
frozen at 80°C, melted, suspended in appropriate volumes of lysis buffer (50
mM Tris, pH 8.0, containing 500 mM NaCl, 1% Triton X-100, 1 M pepstatin A,
and 1 mM phenylmethylsulfonyl fluoride [PMSF]), disrupted by four 30-s sets of
sonication, and centrifuged at 17,000  g for 15 min at 4°C. To confirm the
recombinant protein production in the supernatants, we carried out SDS–10%
PAGE and Coomassie brilliant blue (CBB) staining using CBB R-250 (Sigma).
Bovine serum albumin (BSA) was used as a concentration standard.
GST pull-down assay. The GST pull-down assay was carried out by using the
soluble fractions including recombinant proMMP3, GST, and GST-fused pro-
teins as described above. Twenty microliters of glutathione-Sepharose 4B beads
(GE Healthcare) was washed once with 500 l of the Tris buffer (50 mM
Tris-HCl, pH 7.5, containing 150 mM NaCl, 1 mM EDTA, and 1% Triton X-100)
with protease inhibitors (0.5 mM PMSF and 1 M pepstatin A). The beads were
mixed with the soluble fractions containing 3, 10, or 30 g of GST-fused recom-
binant proteins in 500 l of the Tris buffer, and the soluble fraction containing
10 g of recombinant proMMP3 tagged with Flag3 was added. The mixture was
rotated for 2 h at 4°C, and the precipitant was washed four times with 500 l of
the Tris buffer. The precipitant was dissolved in 20 l of 2 SDS sample buffer
containing -mercaptoethanol, was boiled at 95°C for 5 min, and was separated
by SDS–10% PAGE. Western blot analysis was performed using an anti-Flag M2
antibody (Sigma) or anti-GST antibody (GE Healthcare).
Animals, tissue preparation, and immunohistochemistry. The hind limbs of
8-week-old female BALB/c nu/nu mice (Clea, Tokyo, Japan) were fixed with
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10% neutral phosphate-buffered formalin. The experimental osteoarthritis was
induced by injecting monoiodoacetic acid (MIA; Sigma) into the intraarticular
spaces of 6-month-old Wister rats, as described previously (36). These proce-
dures were approved by the Animal Committee of the Okayama University
Dental School. The animals were processed for histological analysis at 6 weeks
after the injections. The specimens were decalcified in a 14% EDTA solution for
2 to 3 weeks and then embedded in paraffin, and the sections were prepared.
After deparaffinization, the antigen in the section was activated by immersion in
10 mM target retrieval solution (Dako) in a microwave oven operating for 2 min.
The sections were blocked in TBS with 10% FBS for 10 min and incubated with
the anti-MMP3 C-terminal antibody (1:100) in TBS containing 3% BSA at 4°C
overnight. Afterwards, the sections were incubated with anti-rabbit IgG tetra-
methyl rhodamine isothiocyanate conjugate (1:100) for 1 h in TBS containing 3%
BSA and subsequently were incubated with 10 nM Sytox green nucleic acid stain
(Molecular Probes, Invitrogen) in TBS for 1 h. Fluorescent medium (Dako) was
used for mounting. The sections were observed by confocal laser scanning mi-
croscopy.
Statistics. Data were expressed as means 	 standard deviations, and the
statistical significance of differences in mean values was assessed by Student’s
unpaired t tests. Differences among the mean values were considered significant
at a P of 
0.05.
RESULTS
MMP3 in the cell nucleus. To identify TRENDIC-binding
nuclear factors, we performed Southwestern screening by using
a cDNA library of HCS-2/8 cells, since TRENDIC was first
identified as an enhancer element dominant in these cells (7).
Among the three genes cloned (Table 1), we further analyzed
MMP3, because MMP3/stromelysin-1 is known to have an im-
portant role in cartilaginous tissues, although it had been rec-
ognized to act in the extracellular environment. In order to
investigate if MMP3 was present in the cell nucleus, we pre-
pared subcellular fractions of HCS-2/8 cells and analyzed the
distribution of MMP3 by Western blotting. Surprisingly,
MMP3 was detected in the nuclear extract of HCS-2/8 cells
(Fig. 1A). The molecular weight of the major nuclear MMP3
was confirmed to be identical to that of rhMMP3 by Western
blotting with antibody against the MMP3 CAT domain (Fig.
1A). Next, we further analyzed MMP3 in a variety of subcel-
lular fractions by using an anti-MMP3 C-terminal antibody.
Initially, the quality of subcellular fractions was verified. We
detected histone H3 as well as the transcription factor Sox6
specifically in the nuclear fraction, -tubulin in the cytosolic
fraction, cathepsin D in cytosolic and membrane/organelle
fractions, and lamin A/C in the cytoskeletal matrix fraction
(Fig. 1B, left). The distinct localization of these marker pro-
teins verified the purity of the fractions. Among these frac-
tions, FL and putative fragments of MMP3 were distinctly
detected in the nuclear fraction (Fig. 1B, center). MMP3 also
was detected immunocytochemically in the nuclei of HCS-2/8
cells. The signal of MMP3 overlapped with that of the nuclear
stain DAPI (Fig. 1C). Finally, the existence of MMP3 inside
the circle of lamin A/C, which is a component of the nuclear
lamina, was confirmed by confocal laser scanning microscopy
(Fig. 1D). We also detected a significant amount of secreted
MMP3 in the cell culture supernatant of HCS-2/8 as evaluated
by an ELISA (480 ng/ml) (Fig. 1B, right). Taking these findings
together, we confirmed that MMP3 was actively synthesized in
HCS-2/8 cells and was secreted or/and translocated into the
nuclei.
DNA-binding ability of MMP3. We originally cloned MMP3
as a DNA-binding factor (Table 1). To examine whether
MMP3 could bind to TRENDIC or not, we first performed
EMSAs. The TRENDIC probe (pTRENDIC) was shifted in
the gel with nuclear proteins of HCS-2/8 cells (Fig. 2A, lanes 1
and 2), as observed previously (7). The band shift was attenu-
ated by the anti-MMP3 PEX repeat antibody (Fig. 2A, lane 5)
but not by the addition of other anti-MMP3 antibodies (Fig.
2A, lanes 3 and 4). The control anti-rabbit IgG also did not
interrupt the protein-TRENDIC interaction (data not shown).
We also examined the interruptive effect of the PEX antibody
on the interaction of nuclear proteins with BCE1/TbRE and
Seq2 probes, which are other enhancers in the CCN2/CTGF
promoter (7, 13). The band shift of pBCE1/TbRE or pSeq2
also was attenuated by the PEX antibody (Fig. 2B, lanes 3 and
6), indicating that MMP3 also is involved in the gene regula-
tion mediated by these elements.
To confirm the specificity of the TRENDIC-MMP3 binding,
a competitive EMSA was performed. The probe-protein inter-
action was inhibited by the addition of cold TRENDIC in a
dose-dependent manner (10-, 100-, or 1,000-fold excess of cold
TRENDIC) (Fig. 2C).
To further examine the interaction between the genomic
CCN2 enhancer and the nuclear MMP3, we carried out a ChIP
assay. In the chromatin immunoprecipitate obtained from
HCS-2/8 cells by using anti-MMP3 antibody, the genomic
CCN2 enhancer region between positions 292 and 88,
which contains enhancers such as TRENDIC, BCE1/TbRE,
and Seq2, was detected by the ChIP assay (Fig. 2E). No such
signal was detected without the anti-MMP3 antibody (Fig. 2E).
The open reading frame (ORF) fragment of GAPDH was not
detected by the ChIP, either with or without the anti-MMP3
antibody (Fig. 2E). Both the genomic CCN2/CTGF enhancer
region and the ORF fragment of GAPDH were detected in the
cross-linked chromatin sample before immunoprecipitation
(Fig. 2E). These results indicate that MMP3 exists in the pro-
tein complex, binding to the CCN2 enhancer region. Taken
together, these results indicate that MMP3 not only interacted
in vitro with dsDNA having the enhancer sequences but also
interacted in situ with the genomic CCN2/CTGF enhancer
region in the HCS-2/8 cells.
Effects of intracellular MMP3 on CCN2 promoter activity.
To clarify if MMP3 could modulate the CCN2 promoter ac-
tivity, we cotransfected several cell lines with an MMP3 expres-
sion vector (p3xFlagMMP3-myc; schemed in Fig. 3A) and
CCN2 promoter reporter constructs and then quantified the
promoter activity by conducting luciferase assays. MMP3 ex-
pression by transient transfection was confirmed by immuno-
blotting (Fig. 3B). The intracellular overexpression of MMP3
activated the CCN2/CTGF promoter (Fig. 3C, D). TGF- and
intracellular MMP3 synergistically activated the CCN2/CTGF
promoter (Fig. 3C). The CCN2 promoter activity with MMP3
overexpression was 2.2-fold higher in HCS-2/8 cells, 1.8-fold
higher in MDA231 cells, and 2.2-fold higher in COS7 cells than
in their controls (Fig. 3D). In contrast, the effect of overex-
pressed MMP3 was not significant in HeLa or SaOS-2 cells
(Fig. 3D). It should be noted that the relative CCN2 promoter
activity in HCS-2/8 and MDA231 cells was over 30-fold higher
than that in SaOS-2 and HeLa cells (data not shown). To
further investigate this mechanism, we utilized mutants of the
CCN2 promoter (Fig. 3E). Mutants pDS4 and pDS5, lacking
the element between 202 and 88, lost the response to
overexpressed MMP3 in HCS-2/8 cells (Fig. 3F). The response
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of the CCN2 promoter to overexpressed MMP3 was dimin-
ished by the mutagenesis of TRENDIC but not by that of SBE
or BCE1/TbRE in HCS-2/8 cells (Fig. 3G). Also, in MDA231
cells the TRENDIC mutant of the CCN2 promoter lost the
response to overexpressed MMP3 (Fig. 3H). However, in con-
trast to the result obtained with HCS-2/8 cells, mutations in
BCE1/TbRE deprived the CCN2 promoter of the response to
overexpressed MMP3 in MDA231 cells (Fig. 3H). Based on
these results, we concluded that TRENDIC mediated the ef-
fect of MMP3 on the activation of the CCN2 promoter in
chondrocytic cells. Interestingly, our data also indicated that
MMP3 could enhance the CCN2 promoter activity in collabora-
tion with another enhancer element, BCE1/TbRE, in MDA231
cells but not in HCS-2/8 cells.
Effects of MMP3 knockdown on CCN2 gene expression. To
investigate if the endogenous MMP3 was involved in the abun-
dant production of CCN2 from HCS-2/8 cells (7, 9), we
knocked down MMP3 mRNA by RNA interference technol-
ogy and evaluated the effect of the siRNA on CCN2 mRNA
and protein expression and promoter activity. Transient trans-
fection of siMMP3-1369 (20 nM) decreased MMP3 mRNA
expression to 14% of the control dsRNA (siNC) level (Fig. 4A,
left), indicating that siMMP3-1369 successfully degraded
MMP3 mRNA. Under the condition of MMP3 being knocked
down, the CCN2 mRNA level also was decreased to 70% of
the control level (Fig. 4A, right).
Next, to evaluate the effect of the MMP3 siRNA (siMMP3)
on MMP3 and CCN2 protein production, 0, 20, 50, or 100 nM
FIG. 1. Detection of nuclear MMP3 by using its specific antibodies. (A) Immunoblotting of MMP3 in the lysate (Ly) or in the nuclear extract
(Nu) of HCS-2/8 cells. The lysate, nuclear extract, or rhMMP3 (control) was analyzed by immunoblotting using an anti-MMP3 antibody (4190;
Sigma). (B) Immunoblotting analysis of cytosolic (Cy), membrane and cellular organelle (MO), nuclear (Nu), and cytoskeletal matrix (CM)
subcellular fractions prepared from HCS-2/8 cells. Successful fractionation was confirmed by the immunoblotting of fraction marker molecules
(left). MMP3 in the subcellular fractions was detected by immunoblotting using the anti-MMP3 PEX antibody (center). FL and shorter forms of
MMP3 were detected. The total lysate from HCS-2/8 cells also was tested. The level of MMP3 in cell culture supernatant (S) and DMEM
containing 10% FBS (NC) was quantified by using ELISA (right). (C) Immunocytochemistry of MMP3 in HCS-2/8 cells. Cells were stained with
the anti-MMP3 C-terminal antibody (red), and DNA was stained with DAPI (blue). MMP3 colocalized with DNA (purple in the merged view).
Bar, 50 m. (D) Immunocytochemistry of MMP3 (green) and lamin A/C (red) observed by confocal laser scanning microscopy. MMP3 detected
by a specific antibody (M4190; Sigma) was observed in the circle of lamin A/C, indicating its localization in the nucleus. Bar, 5 m.
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of siMMP3-1302 or control dsRNA (siNC) was transfected
into HCS-2/8 cells, and MMP3, CCN2, and GAPDH protein
production in the lysate was evaluated by Western blotting. As
a result, the levels of FL MMP3 (Fig. 4B, upper left) and
MMP3 fragments (Fig. 4B, upper right) decreased in a dose-
dependent manner, while the levels of these MMP3 molecules
were not decreased by control dsRNA transfection. Under the
MMP3 knockdown conditions, the CCN2 protein level also
was decreased (Fig. 4B, lower left) compared to that with
control dsRNA. The GAPDH protein production level was not
affected by the knockdown of MMP3 (Fig. 4B, lower right).
These results indicate that MMP3 regulates CCN2 gene ex-
pression in HCS-2/8 cells. In agreement with this finding,
the CCN2 promoter activity was attenuated down to 40% of
the control level in HCS-2/8 cells (Fig. 4C, left) and 60% of the
control level in MDA231 cells (Fig. 4C, right) by the siMMP3-
1369 transfection.
To further confirm the regulation of CCN2 gene expression
by MMP3 in HCS-2/8 cells, a retroviral vector that expressed
shMMP3 or scrambled shRNA was constructed and infected
into HCS-2/8 cells, and MMP3 and CCN2 expression was eval-
uated 2 weeks after the infection. The shMMP3 retroviral
vector successfully knocked down the level of expression of
MMP3 mRNA to 35% of that of the control (Fig. 4D, left). In
the retrovirus-mediated long-term MMP3 knockdown condi-
tion, CCN2 mRNA expression was as low as 28% of the con-
trol level (Fig. 4D, right).
If MMP3 is a critical and general regulator of CCN2, the
expression of CCN2 is anticipated to be significantly lower in
other cells without MMP3 expression. To confirm this, we
comparatively analyzed the expression of CCN2 and MMP3 in
HCS-2/8 and HeLa cells. In contrast to its expression in HCS-
2/8 cells, MMP3 mRNA expression was deficient in HeLa cells
(Fig. 4E). As we expected, the CCN2 expression level in HeLa
cells was strikingly low (12%) compared to that in HCS-2/8
cells. These results indicate that abundant MMP3 regulates
CCN2 gene expression in HCS-2/8 cells, while CCN2 expres-
sion in HeLa was low because of the deficiency of MMP3, a
FIG. 2. DNA-binding ability of MMP3. (A) The binding of the nuclear protein to pTRENDIC was interrupted by anti-MMP3 PEX antibody
(lane 5). Nuclear extracts from HCS-2/8 cells were preincubated with anti-MMP3 antibodies, and then the pTRENDIC probe was added to the
reaction mixture. Anti-MMP3 antibody abbreviations are the following: N, anti-N-terminal; Hi, anti-Hinge region; PEX, anti-PEX. The blot shown
is representative of three different experiments with similar results. Ab, antibody. NE, nuclear extract. (B) The MMP3 PEX antibody also blocked
the binding of pBCE1/TbRE or pSeq2 by nuclear proteins (lanes 3 and 6). The blot shown is representative of three different experiments with
similar results. (C) The TRENDIC binding of a protein in the nuclear extracts was blocked by cold TRENDIC in a concentration-dependent
manner. (D) The genomic CCN2 enhancer region was coimmunoprecipitated by the anti-MMP3 antibody (4190; Sigma). After the chromatin from
HCS-2/8 cells was cross-linked, immunoprecipitation was carried out with or without the anti-MMP3 CAT domain antibody, and subsequently PCR
was performed for the detection of the genomic CCN2 enhancer region between 292 and 88. The genomic CCN2 enhancer region was
specifically amplified by the ChIP assay with the anti-MMP3 antibody but was not detected without the antibody (control). The ORF of GAPDH
was not amplified by the ChIP with or without the anti-MMP3 antibody (MMP3). Both the CCN2 enhancer region and GAPDH were detected
in the chromatin before immunoprecipitation (positive control).
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crucial factor in CCN2 induction. Additionally, both MMP3
and CCN2 expression levels in SaOS2 osteoblastic cells were
quite low (data not shown). Taken together, these data dem-
onstrated that cellular MMP3 regulates CCN2 gene expression
at the transcription level.
MMP3 domains required for CCN2/CTGF promoter activa-
tion. In order to determine the involvement of individual do-
mains of MMP3 in the CCN2/CTGF trans-activation function,
several assemblages of MMP3 domains were expressed in
COS7 and HCS-2/8 cells, and the CCN2/CTGF promoter re-
porter assay was carried out. The expression of the MMP3
domain deletion mutants in COS7 cells was confirmed by
Western blotting (Fig. 5C). The FL and active forms of MMP3
trans activated the CCN2/CTGF promoter, while the prodo-
FIG. 3. MMP3 overexpression activated the CCN2 promoter via TRENDIC. (A) Schematic representation of the MMP3 expression construct
p3xFlag-MMP3-myc. This construct did not include the coding sequence for the secretion peptide signal. (B) Production of MMP3 from HCS-2/8
cells transfected with p3xFlag-MMP3-myc. HCS-2/8 cells were transfected with the MMP3 expresser or an empty vector. The overexpressed MMP3
in the cell lysate was immunoblotted by using anti-Flag and anti-Myc tag antibodies. (C) Synergy of MMP3 and TGF- on CCN2/CTGF promoter
activation. Intracellular MMP3 overexpression activated the CCN2/CTGF promoter. The MMP3 activation of the CCN2/CTGF promoter was
enhanced by the addition of TGF-. *, P 
 0.05 (n  4). vec., vector. (D) Effect of MMP3 overexpression on the CCN2 promoter. Different types
of cell lines were cotransfected with the p3xFlag-MMP3-myc or empty vector and the CCN2 promoter-luciferase construct (pTS589). The CCN2
promoter was activated by MMP3 overexpression in HCS-2/8, MDA231, and COS7 cells. No significant response was observed in HeLa or SaOS-2
cells. (E) Schematic representations of the mutants of the CCN2 promoter reporter constructs. The enhancer elements involved are indicated.
Mutations are represented by slashes. Luc., luciferase. (F) The response of the CCN2 promoter to MMP3 overexpression was diminished by
deleting the elements located between 202 and 88 (compare DS3 and DS4). (G) Mutagenesis of TRENDIC diminished the response of the
CCN2 promoter to MMP3 overexpression in HCS-2/8 cells. The SBE mutant (muSBE) or the BCE1/TbRE mutant (muTbRE) still was responsive
to MMP3 overexpression in HCS-2/8 cells. These results indicate that MMP3 trans activated the CCN2 gene via TRENDIC in HCS-2/8 cells.
(H) Mutagenesis of either TRENDIC or BCE1/TbRE diminished the response of the CCN2 promoter to the overexpressed MMP3 in MDA231
cells. *, P 
 0.05 (n  3 or 4). NS, not significant.
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main alone did not (Fig. 5A). Interestingly, the PEX domain of
MMP3 lacking a CAT domain trans activated the CCN2/CTGF
promoter in the cells, and the trans activation ability of the
MMP3 PEX domain was comparable to that of the FL and
active form (Fig. 5A). Moreover, CATHinge also trans acti-
vated the CCN2/CTGF promoter, while Hinge alone had no
effect for trans activation (Fig. 5A). Similar results of MMP3
domain functions were obtained in HCS-2/8 cells (Fig. 5A and
B). These results clarified that not only the FL and active forms
of MMP3 but also a few MMP3 fragments, such as PEX and
CATHinge domains, could trans activate the CCN2/CTGF
promoter.
A proteolytic activity of MMPs has been known to be zinc
dependent. In the part of the CAT domain forming the active
site, a Zn2 ion is coordinated by a chelate bond with three
histidine residues found in the conserved sequence HEXX
HXXGXXH and is called a zinc-binding motif. The change of
any one of the histidines to arginine was reported to cause the
loss of the proteolytic activity of MMPs (27). To clarify if the
trans-activation ability of MMP3 for CCN2 expression is de-
pendent on proteolytic activity or not, we constructed plasmids
expressing catalytically dead mutants of MMP3. As a result,
the alteration of a histidine residue at position 218 (H218) to
arginine (H218R mutant) resulted in a decrease of the trans-
activation ability of MMP3 for the CCN2 promoter (Fig. 5D).
The H228R mutant and the double mutant (H218R/H228R)
yielded similar results (Fig. 5D). Both the CAT domain and
the PEX domain lacking the CAT domain hold the trans-
activation ability (Fig. 5A, B). Taking these findings together,
the trans-activation ability of MMP3 for the CCN2 promoter is
partly dependent on the catalytic activity, and the PEX domain
greatly contributes to the activation of the CCN2 promoter.
Uptake and nuclear translocation of extracellular MMP3.
Next, to clarify the subcellular dynamics of MMP3, we pre-
pared Cy3-labeled rhMMP3 (Cy3-MMP3), added it to the me-
dium of HCS-2/8 cells in culture, and observed its behavior
with a confocal laser scanning microscope. The Cy3-MMP3
signals emanated from the cellular membrane or cytoplasm
between 5 and 60 min after the addition of Cy3-MMP3 to the
cell culture (Fig. 6A, images b to f, i, and j). Of note, Cy3-
FIG. 3—Continued.
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FIG. 4. Effects of MMP3 siRNA on CCN2 gene expression. (A) Knockdown of MMP3 also downregulated CCN2 gene expression. mRNA expression
of MMP3 or CCN2 was quantified after the transfection of HCS-2/8 cells with siMMP3 or negative control dsRNA (siNC). siMMP3 knocked down the
MMP3 mRNA to 15% of the level of the control while decreasing the amount of CCN2 mRNA to 70% of the control. (B) The knockdown of MMP3
also decreased the amount of cell-associated CCN2/CTGF protein. Negative control RNA (siNC) or siMMP3 was transfected at a final concentration
of 20, 50, or 100 nM into HCS-2/8 cells. MMP3, CCN2, or GAPDH protein in the cell lysate at 48 h after the transfection was analyzed by Western
blotting. R indicates the transfection-reagent-only control. Levels of FL (left upper panel, short exposure) or fragments (right upper panel, long exposure)
of MMP3 were decreased by the knockdown. Under the MMP3 knocked-down condition, CCN2/CTGF protein also was decreased (left lower panel),
indicating that MMP3 regulates CCN2. (C) CCN2 promoter activities under the condition of the MMP3 knockdown, as quantified by luciferase assays.
siMMP3 also downregulated the CCN2 promoter activities in HCS-2/8 cells (to 40% of the control level) and also in MDA231 cells (to 60% of the
control). (D) Retrovirus-mediated MMP3 knockdown decreased CCN2 mRNA expression. HCS-2/8 cells were infected by a retroviral vector that
expressed shMMP3 or scrambled shRNA (Scr.), and then the mRNA expression levels of MMP3 and CCN2 at 2 weeks after the infection were analyzed by
real-time PCR. MMP3 mRNA expression was successfully knocked down to 35% of the control level (Scr.). The CCN2 mRNA level under the MMP3
knockdown condition was 28% of the control level (Scr.). (E) Relative MMP3 and CCN2 expression levels in HCS-2/8 and HeLa cells.MMP3mRNA expression
was deficient in HeLa cells (left), whileCCN2mRNA expression in HeLa cells was 13% of that in the HCS-2/8 cells. These results indicate that MMP3 is a major
regulator for CCN2 gene expression. *, P 
 0.05 (n  3 or 4); #, below the detection limit.
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MMP3 signals also were observed in the cell nuclei between 15
and 30 min after the addition (Fig. 6, images f to i). The
Cy3-MMP3 signal was barely detected at 60 min after the
addition, indicating the possibility of degradation or resecre-
tion. The Cy3-MMP3 localization in the Cy3-MMP3-positive
cell population was quantitatively analyzed (Fig. 6B). The Cy3-
MMP3 was taken up into the cells within 5 min after the
addition, showing dominant localization in the cytoplasm,
which was followed by the translocation into the nucleus be-
tween 15 and 60 min after the addition. Additionally, to dem-
onstrate that MMP3-Cy3 was certainly in the nucleus, a se-
quential horizontal view of the MMP3-Cy3 signal and DNA in
FIG. 5. Effects of MMP3 domains for CCN2/CTGF promoter regulation. (A) Schemes of MMP3 domains expressed from p3Flag-myc vector
(vec.) in COS7 cells (left). Effects of the MMP3 domains on the CCN2/CTGF promoter in COS7 cells were quantified (graph on the right). The
FL and active forms of MMP3 trans activated the CCN2/CTGF promoter, while the prodomain alone did not (compare empty vec., FL, prodomain,
and active-form results). Interestingly, the PEX domain of MMP3 lacking the CAT domain trans activated the CCN2/CTGF promoter in the cells.
Moreover, the CATHinge domain also trans activated the CCN2/CTGF promoter, while Hinge alone had no effect on trans activation (compare
CATHinge and Hinge results). *, P 
 0.05 (n  3 to 4). (B) Schemes of MMP3 domains expressed in HCS-2/8 (left). The PEX domain and the
CATHinge domain also activated the CCN2/CTGF promoter in HCS-2/8 cells (right). *, P
 0.05 (n 3 or 4). (C) The expression of the MMP3
domains in COS7 cells was confirmed by Western blotting. (D) Catalytically dead mutants of MMP3 expression resulted in the decreasing of the
trans-activation ability for the CCN2 promoter. To remove the catalytic activity, H218R, H228R, and H218R/H228R (Double) mutations in the
HEXXHXXGXXH zinc-binding motif were introduced in the pMMP3 construct. These results clarified that not only the FL and active forms of
MMP3 but also individual MMP3 domains, such as PEX and CATHinge, can trans activate the CCN2/CTGF promoter. *, P 
 0.05 (n  3 or
4); #, P 
 0.05 (n  3 or 4). WT, wild type.
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FIG. 6. Extracellular MMP3 was internalized into the cells and translocated into the nucleus. (A) Cy3-MMP3 was added to the culture medium of
HCS-2/8 cells. The cells were fixed at 0 (a), 5 (b to d), 15 (e to g), 30 (h, i), or 60 min (j) after the addition of MMP3 and then were observed under a
confocal laser scanning microscope. Red signals indicate Cy3-MMP3, and green signals indicate DNA. Cy3-MMP3 was observed on the cell surface or
in the cytoplasm between 5 and 60 min after the addition (b to f, i, and j). Cy3-MMP3 was observed in the nuclei at 15 and 30 min (f to i). Bars, 5 m.
(B) Quantitative analysis of the Cy3-MMP3-positive cells in relation to subcellular localization. N, nucleus; C, cytoplasm; N/C, both. n  4 to 7.
(C) Sequential view of the cells by using confocal laser scanning microscopy revealed that MMP3-Cy3 (red) is inside the nucleus filled with DNA (green).
(D) Effect of LMB on the activation of theCCN2/CTGF promoter by intracellular MMP3 expression. The addition of LMB (20 ng/ml) enhanced both the basal
level and the trans-activation effect of MMP3 for the CCN2/CTGF promoter. *, P 
 0.05 as indicated by brackets (n  4). vec., vector.
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a cell was presented (Fig. 6C). These observations clarified that
extracellular MMP3 is taken up into the HCS-2/8 cells and
subsequently translocated into the nucleus.
Effect of LMB on the induction of CCN2/CTGF by MMP3.
In order to demonstrate that nuclear translocated MMP3 trans
activates the CCN2/CTGF promoter, leptomycin B (LMB) was
employed. LMB is an antibiotic with membrane permeability,
and it has been known to inhibit the nuclear export function of
CRM1/exportin 1 by directly binding to its cysteine residue.
We hypothesized that the nuclear export of MMP3 could be
CRM1 dependent, and thus LMB could cause the nuclear
accumulation of MMP3 and the enhancement of the activation
of the CCN2/CTGF promoter by nuclear MMP3. Exactly as we
predicted, LMB enhanced the trans-activation effect of MMP3
on the CCN2/CTGF promoter (Fig. 6D). The increase in the
CCN2 promoter activity without MMP3 overexpression may
represent the effect of LMB on endogenous MMP3. These
results represent that nuclear-cytoplasmic trafficking is cru-
cial in the trans activation of the CCN2/CTGF promoter by
MMP3.
Domain structure and nuclear localization signals of MMP3.
In addition to the classical domain structure of MMP3, we found
and predicted several novel domains and signal sequences in
MMP3 (Fig. 7A). As an anti-MMP3 PEX antibody blocked pro-
tein-DNA interactions, a DNA-binding domain can be included
in the PEX domain. The Hinge region has been known to be just
a linker; however, it contains proline-rich sequences found in
some transcription factors. The signal sequence at the amino
FIG. 7. Domain structure of MMP3 and putative nuclear trafficking signals. (A) MMP3 mRNA is schematized at the top with the first AUG
codon, the UAG stop codon, and the positions of the siRNA targets (siMMP3-1369 and siMMP3-1302). The domain structure of MMP3 is
illustrated in the middle. SS indicates the secretion signal sequence containing the proline helix breaker at the fifth amino acid. This may result
in sorting MMP3 to the ER-Golgi secretion pathway as well as the cytoplasm after the signal sequence emerges from the ribosome. The prodomain
(Pro) also is designated a putative peptidoglycan-binding domain. The CAT domain also is designated the ZnMc domain, which is conserved
among zinc-dependent metalloproteinases. The hinge region is a linker domain characterized by a proline-rich (P rich) structure. The PEX domain
was revealed to be a DNA-binding domain that forms a propeller-like structure. Putative NLSs in MMP3 are mapped beneath the structure. A
putative NES containing four leucines also was found. (B) List of NLSs in MMP3 and schematically depicted EGFP-NLS fusion proteins. The
arginine (R)- and lysine (K)-rich sequences were picked up from the FL amino acid sequence of MMP3 and were designated NLS0 to NLS5. The
cDNAs encoding these NLSs were cloned into the pEGFP-C1 vector. Arginine and lysine residues are indicated by boldface. The positions of
the NLSs in proMMP3 and the domain in which the NLSs were found are shown. PEX, hemopexin-like repeat. NLS1, NLS2, and NLS3 in MMP3
also were predicted by using PSORTII pattern 4 (pat4) or pat7. (C) Subcellular localization of the GFP-NLSs. The subcellular localization of
EGFP-NLSs and the control (Cont.) was examined in COS7 cells by confocal laser microscopy. EGFP-NLS1, EGFP-NLS4, and EGFP-NLS5 were
observed in the nuclei as well as in the cytoplasm. Similar results were obtained for EGFP-NLS0, EGFP-NLS2, and EGFP-NLS3 (data not shown).
EGFP-MCS (control) was observed only in the cytoplasm. Scale bars, 5 m. The photogram is representative of 10 independent cells with similar
results.
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terminus of MMP3 contains proline at the fifth position. It can
work as a helix breaker, causing the partition sorting of MMP3 to
the endoplasmic reticulum (ER)-Golgi secretion pathway as well
as to the cytoplasm (44). A leucine-rich sequence in the PEX
domain can work as a nuclear export signal (NES).
Classically, the nuclear import of proteins is mediated by
importins  and , which recognize basic amino acid clusters,
designated NLSs, on the protein to be imported (3, 34). In
order to assess if MMP3 entered the nucleus via this classical
pathway, we sought putative NLSs in MMP3. Six lysine- and
arginine-rich sequences were found in the amino acid se-
quence of MMP3, and we designated them NLS0 to NLS5
(Fig. 7A, B). The putative NLSs were scattered among all of
the domains of MMP3. Since MMP3 can be (auto)cleaved, the
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scattered NLSs can function individually in the resultant frag-
ments. In order to investigate the function of individual NLSs,
we constructed the EGFP-NLS expression plasmids for all six
putative NLSs in MMP3, overexpressed them in COS7 cells,
and observed their subcellular localizations. The native EGFP
(control) was observed only in the cytoplasm and not in the
nucleus (Fig. 7C). Surprisingly, all EGFP-NLSs were observed
in the nuclei as well as in the cytoplasm, as shown in Fig. 7C
(data not shown for NLS0, NLS2, and NLS3). These results
indicate the possible involvement of the NLS-mediated classi-
cal pathway in the nuclear translocation of MMP3 even for the
FL and the fragments of MMP3.
Identification of NuMAPs. If MMP3 plays a certain role in
the nuclei, it should be associated with other proteins to exhibit
the downstream phenomenon, whether it cleaves them or not.
To clarify this point, we applied the nuclear extract of HCS-2/8
cells to anti-MMP3 antibody columns and then eluted the
bound proteins and analyzed them by using an LC-MS/MS
system (Fig. 8A). Identified proteins included heterochromatin
proteins, transcription activators/repressors, RNA polymerase
II, nucleosome/chromatin assembly protein, and others (Table
2 and data not shown). Among them, we confirmed the mRNA
expression of HP1, HP1, NF45/interleukin enhancer bind-
ing factor 2 (ILF2), NCoR1, and CAFp48/RBBP4/RbAp48 in
the cells; thereafter, we prepared their GST-fused recombi-
nant proteins and recombinant MMP3 (Fig. 8B, C). The bind-
ings of HP1, NF45, NCoR1, and CAFp48 to MMP3 were
confirmed from the results of a GST pull-down assay (Fig. 8D);
thus, these proteins were designated NuMAPs. These data
suggest that MMP3 associated with these NuMAPs in the
nucleus in exerting its nuclear function.
To clarify the function of these NuMAPs and the collabo-
rative function with intracellular MMP3 for CCN2/CTGF tran-
scription, mammalian NuMAP expression plasmids were con-
structed (Fig. 8E) and coexpressed in HCS-2/8 cells for a
reporter gene assay. HP1 recently was found to exhibit mul-
tiple functions beyond heterochromatin formation (19). In our
study, the overexpression of HP1 activated the CCN2/CTGF
promoter (to a level 2.5-fold above that of the control),
while the expression of other NuMAPs (NF45, RBBP4, and
DDOST) caused no substantial change compared to that of the
controls [pcDNA3.1() and pcDNA3.1()3HA] (Fig. 8F). In
addition, the coexpression of HP1 and MMP3 synergistically
activated the CCN2/CTGF promoter (Fig. 8G). These results
suggested that HP1, a member of the NuMAPs, regulates
CCN2/CTGF transcription in cooperation with nuclear
MMP3.
FIG. 8. Identification of NuMAPs. (A) The methodology to iden-
tify the NuMAPs. The nuclear proteins extracted from HCS-2/8 cells
were immunoprecipitated by using the anti-MMP3 affinity beads for
the MMP3 CAT domain (Cat.), Hinge region, or PEX antibody or IgG
(control). The eluted proteins were digested with trypsin at the C-
terminal peptide bonds of lysine and arginine. Samples were applied to
the nanoflow high-performance liquid chromatography (HPLC) chip
MS/MS, and the data were analyzed to identify the proteins. The
NuMAP candidates are shown in Table 2. (B) Structures of the re-
combinant MMP3 and several GST-fused NuMAP candidates. Trigger
factor (TF) was added to all of the proteins to increase their solubility.
(C) CBB staining of the recombinant proteins. The soluble fractions (1
or 5 l) or the BSA control was electrophoresed in 10% polyacryl-
amide gels and stained. Arrows indicate the recombinant proteins.
(D) MMP3-NuMAP interactions. Flag-tagged MMP3 (10 g) was
mixed with the GST-fused NuMAP candidates (3, 10, or 30 g) and
then pulled down with glutathione-Sepharose beads. The pulled down
proteins were analyzed by immunoblotting using an anti-Flag or anti-
GST antibody. The direct interaction of MMP3 with HP1, NF45,
NCoR1, and RBBP4 was confirmed. (E) Expression of HA3-tagged
HP1, NF45, RBBP4, and DDOST in COS7 cells. Schemes of the
expression constructs are illustrated on the top. Their expressions were
confirmed by examining the lysates by Western blotting (lower panels).
(F) Trans activation of the CCN2/CTGF promoter by HP1 among
NuMAPs, revealed by using reporter assays. *, P
 0.05 as indicated by
brackets (n  4). (G) Cooperative trans activation of the CCN2/CTGF
promoter by MMP3 and HP1. HCS-2/8 cells were cotransfected with
p802CCN2promoter-luc (400 ng), phRL-TK(int) (100 ng), p3Flag-
myc or pMMP3 (1 g), and p3xHA or pHP1 (1 g) in each well of a
12-well plate for the luciferase assay. *, P 
 0.05 (n  4); #, P 
 0.05
as indicated by brackets (n  4). (H to K) Colocalization of HA3-
tagged HP1 (H), NF45 (I), or RBBP4 (J) with the FL, PEX domain,
or CAT domain of MMP3. Nuclear localization of HP1, NF45, and
RBBP4 was observed. The FL, PEX domain, or CAT domain of
MMP3 was observed to be colocalized with these NuMAPs, and these
MMP3 also were observed in the cytoplasm. (K) The HA3 tag was
faintly observed to be diffused. Scale bars, 5 m. IP, immunoprecipi-
tation; vec., vector.
TABLE 2. List of NuMAPsa
NuMAP(s) Putative function(s) Antibodytype Score
GenBank
accession no.
HP1/CBX5 Heterochromatin, etc. CAT 17.81 6912292
HP1/CBX3 Heterochromatin, etc. PEX 9.82 15680098
NCoR1 trans repression CAT 10.64 35193218
CAFp48/RBBP4/
RbAp48
Chromatin assembly, etc. Hinge 9.3 62897117
ILF2/NF45 trans activation Hinge 10.9 55962125
a The partial list of NuMAPs was identified by coimmunoprecipitation and
LC-MS/MS. The binding abilities of these NuMAPs with MMP3 were confirmed
and are shown in Fig. 8. Anti-MMP3 antibodies used for coimmunoprecipitation
were against CAT, Hinge, and C-terminal PEX domains, and subsequent LC-
MS/MS analysis was performed with the data-analyzing software Spectrum Mill.
The cutoff score for proteins and peptides was 8.0. We subtracted the back-
ground data obtained from a control experiment with IgG from those obtained
with anti-MMP3 antibody.
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MMP3 can be (auto)cleaved into the CAT domain and the
PEX domain in or out of the cells, and the PEX domain and
CATHinge domain possess a trans-activation ability for the
CCN2/CTGF promoter at a level comparable to that of FL
MMP3. In addition, both contain putative NLSs. To clarify the
localization of NuMAPs (HP1, NF45, and RBBP4) with
MMP3s (FL, PEX, and CAT domains), these proteins or do-
mains were coexpressed in COS7 cells, and then the colocal-
ization was investigated by using confocal microscopy. Firstly,
HP1, NF45, and RBBP4 were observed mainly to be localized
only in the nucleus (Fig. 8H to J), while the HA3 tag was
observed to be faintly diffused (Fig. 8K). The FL, PEX, or CAT
domain of MMP3 was observed to be localized in the nucleus
as well as in the cytoplasm. Neither NuMAPs (HP1, NF45,
and RBBP4) nor MMP3s (FL, PEX, and CAT domains) were
observed in the nucleolus (Fig. 8H to K). These findings indi-
cated that HP1, NF45, and RBBP4 can interact with MMP3
in the nucleus in vivo, as demonstrated by in vitro GST pull-
down assays (Fig. 8D). Taking these results together, among all
NuMAPs tested, HP1 can trans activate the CCN2/CTGF
promoter by interacting with MMP3 in the nucleus.
Subcellular localization of MMP3 in normal and osteoar-
thritic cartilaginous tissues. To investigate the relationship
between subcellular MMP3 localization and the pathophysiol-
ogy of articular cartilage in animals, we immunohistochemi-
cally examined MMP3 in normal and osteoarthritic articular
cartilages with a confocal laser microscope. MMP3 was immu-
nopositive in the normal articular cartilage of 2-month-old
mice (Fig. 9A, row a), while control IgG brought no significant
signal. The colocalization of the MMP3 signals with DNA was
very evident at high-power magnification (Fig. 9A, row b). In a
rat osteoarthritic cartilage, the articular and semilunar chon-
drocytes were positively stained by the MMP3 antibody (Fig.
9B). We also observed the colocalization of the MMP3 staining
with DNA in articular chondrocytes at high-power magnifica-
tion (Fig. 9B, rows e and f). MMP3 in the cytoplasm also was
observed in some osteoarthritic articular chondrocytes (Fig.
9B, rows e and f; yellow in merged view). It should be noted
that the fibrochondrogenic cells, in which CCN2 would be
expressed and involved in the tissue remodeling, showed
MMP3 existed alongside DNA (Fig. 9B, row g; yellow in
merged view). The data that MMP3 is localized in the nuclei of
normal developing and osteoarthritic articular chondrocytes in
animals suggest a role of the nuclear MMP3 in the develop-
ment and regeneration of articular cartilage.
Effects of MMP inhibitors on CCN2/CTGF promoter activity
and on nuclear stromelysin-like endopeptidase activity. To
investigate if the proteinase activity of MMP3 was associated
with the observed transcriptional activation of CCN2, we
added MMP inhibitors to the culture medium of HCS-2/8 cells
and subsequently quantified the CCN2 promoter activities. A
specific inhibitor of human MMP3 (MMP3 inhibitor II) sup-
pressed the CCN2 promoter activity in a dose-dependent man-
ner (Fig. 10A). In contrast, a specific inhibitor of MMP2 and
MMP9 did not suppress the CCN2 promoter activity (Fig.
10A), nor did GM6001, a well-known broad-spectrum hydrox-
amic acid inhibitor of MMPs (Fig. 10A). These results indicate
that the structural hindrance caused by the specific inhibitor
blocked the interaction between MMP3 and its binding target,
thus strongly suggesting the involvement of the CAT domain in
the transcriptional activation events.
To determine further if the nuclei of HCS-2/8 cells exerted
stromelysin endopeptidase activity, we tested the ability of a
nuclear extract of HCS-2/8 cells to cleave a fluorogenic sub-
FIG. 9. Immunohistochemical analysis of MMP3 in articular carti-
lage of animals. Sections were stained by using the anti-MMP3 C-
terminal antibody (red) with a fluorescent DNA dye (green) and were
observed by confocal microscopy. (A) Articular cartilage of a 2-month-
old mouse (a) and a high-power magnification view (b). Scale bars, 50
(a) and 10 m (b). The nuclear accumulation of MMP3 in the articular
chondrocytes was clearly evident (yellow in merged views). (B) MMP3
in osteoarthritic articular (c) and semilunar (d) cartilage in the knee
joint of a 6-month-old rat. Two subregions of row c (enclosures) also
were viewed under high-power magnification (e and f). (g) Fibrochon-
drogenic cells also were observed under high-power magnification.
Scale bars, 50 (c and d) and 10 m (e to g). MMP3 (red) was colo-
calized with DNA (green) in the nuclei (arrows) or was distributed in
the cytoplasm (arrowheads).
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strate of stromelysin (32). Initially, the stromelysin activity of
MMP3 (8.3 nM) activated by 1 mM APMA was successfully
detected by measuring the number of RFUs emitted by the
cleavage of the peptide substrate (Fig. 10B). This stromelysin
endopeptidase activity of active MMP3 was blocked by MMP3
inhibitor II or GM6001 but not by the MMP2/MMP9 inhibitor
(Fig. 10B). The endopeptidase activity of proenzyme MMP3
also was tested. Proenzyme MMP3 (1.7 nM) cleaved the flu-
FIG. 10. Characterization of stromelysin-like activity in HCS-2/8 nuclei. (A) Effects of MMP inhibitors on CCN2 promoter activity in HCS-2/8
cells. MMP2/MMP9 inhibitor I (M2/9i), MMP3 inhibitor II (M3i), or GM6001 was added to the culture medium of HCS-2/8 cells at a final
concentration of 0, 0.02, 0.2, 2, or 20 M. The cells were transfected with the CCN2/CTGF promoter reporter 8 h after the addition, and then
reporter gene expression was evaluated 48 h after the transfection. Only MMP3 inhibitor II at a concentration of 20 M suppressed the
CCN2/CTGF promoter activity (to 66% of the control level); however, neither GM6001 nor the gelatinase inhibitor affected the promoter activity.
These results indicate that endogenous MMP3 regulated CCN2/CTGF gene expression via the CCN2/CTGF promoter. *, P 
 0.05 (n  4).
(B) Establishment of the stromelysin activity assay in vitro. A stromelysin-specific peptide substrate, Mca-RPKPVE-Nval-WRK(Dnp)-NH2
fluorogenic substrate, was tested for cleavage by rhMMP3 as well as by a nuclear extract of HCS-2/8 cells, and the endopeptidase activity was
quantified by measuring the RFUs. Active MMP3 (8.3 nM) fully cleaved the peptide in 2 h, and the endopeptidase activity was perfectly blocked
by MMP3 inhibitor II (M3i) or GM6001 but not by the MMP2/MMP9 inhibitor (M2/9i). *, P 
 0.05 (n  4). (C) Proenzyme MMP3 (1.7 nM; 100
ng) cleaved the substrate as well, suggesting autoactivation along the assay. (D) Nuclear extract (NE) of HCS-2/8 cells (100 ng) also cleaved the
substrate. (E) The endopeptidase activity of the nuclear extract was perfectly blocked by 1 mM APMA. w/o, without.
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orogenic substrate relatively slowly (Fig. 10C), suggesting that
proenzyme MMP3 was becoming activated in the reaction
buffer at 37°C. Instead of the recombinant MMP3, we next
tested the stromelysin endopeptidase activity of the nuclear
extract prepared from HCS-2/8 cells. This extract also cleaved
the peptide substrate in a dose-dependent manner; 6 g of the
nuclear extract exerted enough activity to cleave the peptide to
the same extent as 100 ng (1.7 nM) of proenzyme MMP3 (Fig.
10D). These findings support our idea that active forms of FL
or/and smaller forms of MMP3 exist in the nuclei of chondro-
cytes. Unexpectedly, this stromelysin activity of HCS-2/8 nu-
clear extracts was perfectly blocked by 1 mM APMA (Fig. 10E)
but not by any inhibitor tested, i.e., GM6001, MMP3 inhibitor
II, and the MMP2/MMP9 inhibitor (data not shown). Previ-
ously, PEX domain-deleted mini-stromelysin mutants were re-
vealed to show an altered response to APMA, in that precursor
processing was inhibited rather than accelerated (11). In our
data, FL and 35-kDa MMP3 were detected by Western blot-
ting using an anti-MMP3 CAT domain antibody (Fig. 1A). FL
and several shorter MMP3s also were detected by using anti-
MMP3 C-terminal domain antibody (Fig. 1B). Thus, we spec-
ulate that the FL or shorter MMP3s in the nucleus possess
stromelysin activity, which was blocked by APMA. In contrast
to the results of the endopeptidase activity test using nuclear
extracts in vitro, in a reporter gene assay, MMP3 inhibitor II
inhibited the CCN2 promoter activity, whereas GM6001 did
not (Fig. 10E). Therefore, GM6001 may not be able to effi-
ciently enter the cells, and MMP3 inhibitor II may have
blocked the MMP3 action in any of the ensuing steps, e.g., the
release from ECM, endocytosis, or nuclear import, rather than
in the nucleus. These findings suggest that the possible modi-
fication of MMP3 or some interaction partner of MMP3 in the
nucleus protects MMP3 from MMP inhibitors to sustain
stromelysin activity.
Specificity of MMP3-TRENDIC interaction and its consen-
sus sequence. The DNA-binding ability of MMP3 was already
demonstrated in Fig. 2, in which we showed that TRENDIC
and the other cis elements were able to bind MMP3 in the
nuclear extract. To further investigate the sequence specificity
of MMP3-targeted DNA, we initially performed in silico anal-
yses and, subsequently, a competitive EMSA (Fig. 11). TRENDIC
sequences from different species were aligned and compared
(GenBank accession numbers were shown in a previous study)
(Fig. 11A) (7). Obviously, the TRENDIC sequence is highly
conserved among vertebrates (Fig. 11A). The TRENDICs were
92% conserved between human and bovine species. The
TRENDICs also were highly conserved in rodents, particularly
mice and rats (96%). The amphibian TRENDIC sequence was
relatively different from those of other vertebrates (77% con-
served between humans and frogs). Nevertheless, a sequence
FIG. 11. Sequence specificity of MMP3-TRENDIC binding. (A) Sequence conservation of TRENDIC among species. Human, bovine, murine,
rat, and frog TRENDIC sequences are aligned. The nucleotides conserved between human TRENDIC and those of other species are shown in
boldface. The TRENDIC core sequence predicted from the TRENDIC sequences of the species is shown at the top. (B) Alignment of the cis
elements in the human CCN2 promoter. The nucleotides identical to those in TRENDIC are shown in boldface. (C) Specific binding of MMP3
to the CCN2 enhancer sequence in the presence of an excess of nonspecific competitor. Probe CCN2p160, which contains the three enhancers
shown in panel B, was shifted with recombinant MMP3 in a dose-dependent manner in the presence of 0.5 g of poly(dA-dT). (D) The
MMP3-enhancer complex was supershifted with anti-PEX antibody but not with anti-Hinge or control IgG. Poly(dA-dT) (1 g/reaction) was used.
f., free probe; s., shifted probe; s.s., supershifted probe. (E) Sense sequences of modified TRENDIC competitors. The corresponding dsDNAs were
used for the competitive EMSA shown in panel F. (F) The MMP3-p160 interaction was interfered with by TRENDIC but not by its modified
sequences. The competitors (TRENDIC, SeqA, and SeqB; 1-, 10-, 100-fold excesses of probe) were preincubated with rhMMP3 before the addition
of the probe p160 with poly(dI-dC) (0.1 g/reaction). TRENDIC competed with p160 for binding with rhMMP3 (lanes 1 to 3), whereas the SeqA
dsDNA failed to compete with the binding reaction (lanes 4 to 6). SeqB was modestly competitive with the probe (lanes 7 to 9).
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(5-TRRAGTGTGCCAG-3) can be found that is mostly con-
served among all of the species. Next, we aligned TRENDIC,
BCE1/TbRE, and Seq2 sequences shown to interact with nu-
clear MMP3 (Fig. 2A and B and 11B). By the alignment, the
core sequence 5-GAGTG-3 and several flanking nucleotides
were found to be conserved. Importantly, this core sequence
also is involved in the TRENDIC consensus motif described
above. In order to further evaluate the DNA-binding property
of MMP3, we established an EMSA system by using rhMMP3
and a p160 probe containing TRENDIC, BCE1/TbRE, and
Seq2. The p160 probe was shifted by adding rhMMP3 (Fig.
11C) and supershifted by further adding the anti-PEX anti-
body for MMP3 (Fig. 11D), demonstrating that rhMMP3
bound to p160. This MMP3-p160 probe complex was stably
present even in the presence of a vast amount of poly(dI-dC),
ruling out the possibility that the MMP3-p160 interaction is
nonspecific. Moreover, based on the result of the sequence
alignment, we designed mutant TRENDIC sequences (Fig.
11F) and performed competitive EMSAs to examine the spec-
ificity of MMP3-TRENDIC interactions. The SeqA sequence
contains 5-CCAGCTT at the downstream end, whereas SeqB
contains 5-GAGTGTG-3 (the core sequence) in the center.
The dsDNA of wild-type TRENDIC competed with the
MMP3-p160 binding in a concentration-dependent manner
(Fig. 11G, lanes 1 to 3). Perfect competition was not achieved,
probably due to the involvement of SEQ2 and BCE1/TbRE in
p160 or a possible DNA interaction with the zinc-dependent
metazincine (ZnMc)/CAT domain. In contrast, SeqA dsDNA
completely failed to compete with the p160-MMP3 binding
(Fig. 11G, lanes 4 to 6). SeqB was not very competitive with the
probe (lanes 7 to 12), indicating that the core sequence is
necessary but not sufficient to warrant the specific interaction
with MMP3. All of these results demonstrated that the flanking
nucleotide sequences in TRENDIC and the other elements, as
well as the core sequence, determine the specific binding of
certain DNAs to MMP3.
DISCUSSION
In this report, we demonstrated a novel aspect of MMP3;
i.e., that it acted as a transcription factor in cell nuclei. First, we
cloned MMP3 as a gene encoding a TRENDIC-binding factor
(Table 1). Next, the existence of MMP3 in the nuclei (Fig. 1
and 2) was indicated in vitro and also in vivo (Fig. 9). Inter-
estingly, both the nuclear uptake of extracellular MMP3 (Fig.
6) and the nuclear targeting ability of putative NLSs in MMP3
(Fig. 7) were shown. The binding of MMP3 to the DNA cis
elements, especially to TRENDIC, was confirmed by EMSA
(Fig. 2 and 11). Moreover, the interaction between MMP3 and
the genomic CCN2 enhancer region including TRENDIC was
confirmed by the ChIP assay (Fig. 2E). The functional require-
ment for the TRENDIC element in the CCN2 promoter for
MMP3-mediated activation was demonstrated by the mutagen-
esis experiments (Fig. 3). Finally, the regulation of CCN2 gene
expression by MMP3 and by its domains was demonstrated by
overexpression and gene knockdown studies (Fig. 3, 4, and 5).
In addition, HP1 was revealed to be a coregulator with
MMP3 for CCN2/CTGF trans activation (Fig. 8 and Table 2).
An MMP3 inhibitor specifically suppressed the CCN2/CTGF
promoter activity (Fig. 10). All of these data together support
our contention that MMP3 is translocated to the cell nucleus
and, once there, trans activates the CCN2 gene.
In this study, most of the data were obtained by using HCS-
2/8 chondrocytic cells, a cell line that has been a useful model
in chondrocyte biology. The cells have been used as a model of
normal and osteoarthritis chondrocytes in a number of studies
(30, 40, 51). Of note, CCN2 originally was cloned as a hyper-
trophic chondrocyte-specific gene product 24 (Hcs24) from
HCS-2/8 cells and was demonstrated to function as an endo-
chondral ossification-promoting factor (50). Indeed, HCS-2/8
cells produced abundant amounts of CCN2 compared to the
amount produced by other cell types (7, 9). The HCS-2/8 cell
line was established from a chondrosarcoma, but the expres-
sion of CCN2 in cartilaginous tumors is negatively related with
the level of their malignancy (45), indicating that HCS-2/8 cells
can be a model of a normal phenotype of chondrocytes. This
cell line also has been used for arthritis studies, because HCS-
2/8 produces MMP3 and matrix degradation-related molecules
in response to tumor necrosis factor alpha (16, 17, 41). In
addition, MMP3 immunopositive cells were specifically ex-
pressed in normal articular cartilage of a 14-year-old human,
while MMP9, MMP13, and ADAMTS4 were not detected
(H. I. Roach, personal communication). We observed nuclear
MMP3 in both normal and osteoarthritic cartilages (Fig. 8). In
addition, the strong expression of CCN2/CTGF in chondro-
cytes in osteoarthritic tissues already has been reported (36).
Thus, nuclear MMP3 may function when chondrocytes are in a
physiological or pathological status.
The trans activation of the CCN2/CTGF promoter by the
nuclearly translocated MMP3 is a major discovery in this study.
One piece of evidence for this finding is that the knockdown of
MMP3 resulted in a decrease in CCN2/CTGF expression (Fig.
4). Moreover, a major CCN2/CTGF-producing cell line, HCS-
2/8, was found to produce MMP3, while MMP3 expression was
undetectable in HeLa cells that produce small amounts of
CCN2/CTGF (Fig. 4) (7–9). MMP3 is known as a secretory
proteinase that degrades ECM proteins such as proteoglycans
and collagens, while MMP3 also cleaves and activates other
MMPs, such as gelatinases, and growth factors, such as TGF-.
In an analysis of the signal sequence at the amino terminus of
MMP3, proline was found at the fifth position of the sequence.
The proline in the signal sequence can work as a helix breaker
and may result in bisorting between the ER-Golgi secretion
pathway and cytoplasm after the signal peptide emerges from
the ribosome (44). If this partition trafficking occurred, some
MMP3 would be located in the cytosol for further transport to
the nucleus, while other MMP3 would be secreted through the
ER-Golgi complex. This may result in both direct nuclear
transportation from the cytoplasm and the internalization-nu-
clear transportation of MMP3.
The TGF-/Smad signal regulates CCN2/CTGF gene ex-
pression at the level of transcription, and the activation of
TGF- by MMP3 in the extracellular microenvironment can
indirectly activate CCN2/CTGF through TGF-R/Smad sig-
naling (7); however, the intracellular overexpression of MMP3
from the pMMP3 vector trans activated the CCN2/CTGF pro-
moter (Fig. 3). Therefore, we consider that nuclearly translo-
cated MMP3 directly trans activates the CCN2/CTGF gene.
Interestingly, the overexpression of intracellular MMP3 and
TGF- synergistically activated the CCN2/CTGF promoter
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(Fig. 3C). If the Smads and intracellular MMP3 signals are
activated simultaneously, some signal cross talk may occur,
because the MMP3-binding site as well as TRENDIC is lo-
cated immediately upstream of the Smad binding site (SBE) in
the CCN2/CTGF promoter (7). Thus, MMP3 can regulate
CCN2/CTGF transcription directly by itself and through acti-
vating TGF-/Smad signaling. Further investigation about this
signaling cross talk is under way.
MMP3-null mice have been reported to show delayed
wound healing, joint inflammation/osteoarthritis, abnormal
CD4 physiology, increased susceptibility to bacterial infec-
tion, abnormal neuromuscular synapse morphology, and ab-
normal miniature end plate potential (48). CCN2/CTGF has
been known to be a key player in the wound-healing process.
Together with our discovery that nuclear MMP3 regulates
CCN2/CTGF, the insufficient supply of CCN/CTGF in MMP3-
null mice should result in a delayed wound-healing phenotype.
Further investigation by using MMP3-null mice is under way.
We should be careful to explain the mechanism of trans
activation by MMP3 and the novel domain structure of MMP3,
because MMP3 can cleave and activate itself. The overexpres-
sion of the MMP3 deletion mutants revealed that the PEX
domain and CATHinge domain can trans activate the CCN2/
CTGF promoter per se as well as the FL or active form of
MMP3 (Fig. 5A). Catalytically dead mutants of MMP3 de-
creased the trans activation ability for the CCN2 promoter
compared to that of the wild-type MMP3 (Fig. 5D). These
results indicate that both the CAT domain and PEX domain of
MMP3 can activate the CCN2 promoter independently. The
catalytic activity partially contributed to the trans activation of
the CCN2 promoter; however, it is not essential for the trans
activation. For the mechanisms of activation, the involvement
of NuMAPs was strongly suggested (Fig. 8D to G). Indeed,
HP1 synergistically trans activated the CCN2/CTGF promoter
with FL MMP3 (Fig. 8E-G). The cell type-specific trans-acti-
vation mode of MMP3 for CCN2/CTGF may be ascribed to
the cell type-specific involvement of cofactors such as HP1.
Locating the HP1-binding domain in MMP3 also is important
and is under investigation (Fig. 7A).
The DNA-binding domain of MMP3 was revealed to be in
the PEX domain, because the TRENDIC-nuclear protein in-
teraction was blocked by the anti-PEX antibody (Fig. 2A, B).
In sharp contrast, the anti-N-terminal, anti-Hinge antibodies
caused no significant change in the protein-DNA interactions
(Fig. 2A). Moreover, no upper-shift band was observed with
the other anti-MMP3 antibodies by the supershift assay (Fig.
2A). Of note, in another experiment with purified rhMMP3,
the anti-PEX antibody made an upper shift with the MMP3-
p160 complex (Fig. 11D). Several mechanisms can be consid-
ered in accounting for the differential effects of the anti-PEX
antibody in the EMSA. For example, (i) the ZnMc/CAT do-
main can also bind to p160, and such a secondary DNA-bind-
ing domain may be hidden by other factors, such as NuMAPs,
in the nuclear extracts; (ii) the DNA-binding ZnMc/CAT do-
main of nuclear MMP3 may have been cleaved away from the
PEX domain; or (iii) enhanced MMP3 dimerization under the
purified condition may yield a new MMP3 complex that binds
to both DNA and the anti-PEX antibody.
In our study, recombinant MMP3 was translocated from
outside of the cells into the nuclei (Fig. 6). Also, endogenous
MMP3 was in the cells and on the cell surface (Fig. 1C and D
and 9). Recent studies indicated that proMMP2 made a com-
plex with TIMP1 and low-density lipoprotein-related protein 1
(LRP1) and then was internalized into the cells (6, 14). The
LRP1/proMMP2/TIMP2 complex also was reported to be in-
ternalized (10). LRP1 is abundantly expressed in HCS-2/8 cells
(25). We also observed that LRP1 was colocalized with MMP3
in HCS-2/8 cells by using laser confocal microscopy (data not
shown). Thus, MMP3 or the MMP3/TIMP complex may bind
to the trans-membrane type of receptor molecules, such as
LRPs, for internalization into cells. The delivery of certain
molecules into the nucleus from the plasma membrane by
endocytosis already has been reported (3). Therefore, MMP3
may be transported to the nucleus through such a pathway.
The regulation of MMP3 internalization is under investigation
by using LRP1 and its inhibitor receptor-associated protein.
We also found six putative NLSs in MMP3 for nuclear entry
through the nucleopores (Fig. 7). In addition, we found one
putative NES in MMP3 (Fig. 7). Indeed, externally added
rhMMP3 translocated to the nucleus in 30 min, whereas the
amount was decreased at 60 min after the addition (Fig. 6).
This loss of nuclear MMP3 may have been caused by degra-
dation or nuclear export. LMB, which suppresses CRM1-de-
pendent nuclear export, caused the activation of the CCN2/
CTGF promoter (Fig. 6E). This result may be due to the
nuclear accumulation of MMP3 caused by the blockade of
CRM1-mediated nuclear export. Therefore, MMP3 can shut-
tle back to the cytoplasm after being translocated to the nu-
cleus.
Of note, Si-Tayeb et al. (47) also reported an NLS in MMP3
that is the same as one of the NLSs identified in our study (Fig.
7B). It is possible that multiple NLSs are recognized synergis-
tically for efficient nuclear translocation. Also, an NLS must be
exposed on the surface of the molecule to be transported for
recognition by importins for the nuclear translocation from the
cytoplasm. The posttranslational modification of MMP3 can
remove or hide the primary NLS and expose another NLS on
the molecular surface, suggesting the differential use of multi-
ple NLSs. We also identified a RAN-binding protein as an
MMP3-associated protein. This protein is involved in the nu-
clear import event. As such, two independent pathways to the
nucleus are indicated at present. Further investigation will
specify the precise mechanism of nuclear translocation of
MMP3.
We detected FL MMP3 dominantly in the nuclear fraction
of HCS-2/8 cells (Fig. 1) with minor signals for its fragments,
which can exert stromelysin proteolytic activity (Fig. 5). In
addition to stromelysin activity in the nuclear extract of HCS-
2/8 cells, there have been two reports of stromelysin activity in
the nucleus (47, 54). Si-Tayeb et al. (47) reported a 35-kDa
nuclear MMP3 in HepG2 cells that displayed stromelysin ac-
tivity. Of note, a specific MMP3 inhibitor repressed the pro-
moter activity of CCN2 (Fig. 4). Thus, the proteinase activity
may be involved in the trans activation of CCN2 by MMP3. We
speculate that an appropriate amount of nuclear MMP3 is
under the control of TIMPs, so that it can work properly as a
transcription factor, since we also detected TIMP-1 in the
nuclear fraction of HCS-2/8 cells (data not shown). It was
previously reported that TIMP-1 accumulates in the cell nuclei
in association with the cell cycle (54), and multiple roles of
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TIMPs other than their roles as proteinase inhibitors have
been indicated, such as stimulating cell growth and acting as an
antiapoptotic molecule (18). Thus, it is anticipated that MMP3
interacts with TIMPs in the cells as well as in the extracellular
environment. It was reported that the intracellular overexpres-
sion of MMP3 induced apoptosis (47). Here, we have specu-
lated about the mechanism of the apoptosis elicited by cellular
MMP3. One possibility is that a vast amount of cellular/nuclear
MMP3 induces apoptosis by digesting cytoplasmic and intranu-
clear protein components. A death-associated protein that was
identified as one of the NuMAPs may be involved in the ap-
optosis process (data not shown). Another possibility is that
the nuclear MMP3 induces the overexpression of CCN2/
CTGF, which subsequently induces cellular apoptosis (22).
We identified several NuMAPs by performing the coimmu-
noprecipitation study (Fig. 8; Table 2). These putative cofac-
tors included heterochromatin proteins, transcription coacti-
vators, corepressors, RNA polymerase II, chromatin assembly
factors, and others. One may expect to find MMP3 in the
proteins pulled down by the beads with anti-MMP3, but we
found no MMP3. We believe that the elution condition we
employed dissociated MMP3-NuMAP complexes but did not
interfere with stronger antigen-antibody interactions. It also is
possible that TIMPs have not been detected for a similar rea-
son. One of the NuMAPs, HP1, was demonstrated to interact
with MMP3 and to coactivate the CCN2/CTGF promoter with
MMP3 (Fig. 8). Although multiple functions of heterochroma-
tin proteins as transcription factors and as binding targets of
RNA interference machinery (19, 21) have been reported,
heterochromatin proteins are known to recognize the tri-
methylated ninth lysine of histone H3 (H3K9), resulting in chro-
matin condensation (2). Moreover, abundant trimethylated
H3K9, representing the active form of chromatin, was detected
in the promoter regions but not in the enhancer regions (20,
43). Hence, it is possible that nuclear MMP3 binds to HP1/
Swi6, one of the NuMAPs, on the histone of the CCN2 en-
hancer region to trans activate the CCN2 gene. Indeed, we
detected an interaction between MMP3 and the genomic
CCN2 proximal promoter region by ChIP assay (Fig. 4E).
Therefore, native HP1 may collaborate with MMP3 on the
genomic DNA locus in the cells.
As a NuMAP, NCoR1 also was identified, which is a tran-
scription repressor that acts by promoting chromatin conden-
sation and by preventing access to the gene by the transcription
machinery. Another possible mechanism of CCN2 gene trans
activation is that MMP3 degrades NCoR1 to prevent transcrip-
tion repression. Recently, MMP2 was found in the nuclei of
cardiac myocytes and is capable of cleaving PARP in vitro (28).
Thus, PARP can be inactivated or activated by MMP3 itself, or
MMP2 can be activated by MMP3. PARP has been known to
perform poly(ADP-ribosyl)ation of the chromatin DNA for
chromatin DNA maintenance. The cleavage and inactivation
of PARP result in the inhibition of poly(ADP-ribosyl)ation
and expose the DNase hypersensitive region. The exposure of
such naked DNA can supply an MMP3-accessible region on
DNA. Further genetic and epigenetic approaches will clarify
the precise mechanisms of CCN2 induction by MMP3 acting
with such cofactors.
In this report, we showed that MMP3 from outside of the
cells and in the cytoplasm was translocated into the nucleus,
where MMP3 bound to DNA/chromatin and trans activated
the CCN2 gene (Fig. 12). During this process, some of the
NuMAPs may have contributed to this transcription factor-like
function of MMP3. Based on our present findings and numer-
ous past reports, we propose a dual role for MMP3, i.e., its
functioning both extra- and intracellularly. In this model,
MMP3 acts to degrade ECM outside, whereas it induces CCN2
and other matrix-related proteins in the nucleus. This extra-
and intracellular, dual-functioning MMP3 may play an impor-
tant role in the development and matrix remodeling of carti-
lage and bone. Abnormalities in the MMP3 dynamics may be
involved in the MMP/CCN2-related matrix diseases, e.g., os-
teoarthritis and rheumatism, and in fibrotic diseases such as
systemic sclerosis and atherosclerosis. Clarifying and control-
ling the behavior of extracellular/intracellular MMP3 may as-
sist in the establishment of a new therapeutic approach to
combat such matrix-related diseases.
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FIG. 12. Novel transcription factor-like function of MMP3. The
internalization of MMP3 from the cell surface into the cells via a
putative receptor and the successive transportation into the nucleus
were indicated. Another possible pathway is that MMP3 directly trans-
locates to the nucleus after translation. MMP3 binds to the TRENDIC
motif for trans regulation of the CCN2/CTGF gene. This trans regula-
tion can modify the signal in cartilage development, tissue remodeling,
and tissue regeneration through CCN2 molecules and may be involved
in some arthritic diseases. HP1 and certain other NuMAPs contribute
to the transcription factor-like function of MMP3.
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